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Tabebuia avellanedae Lorentz ex Griseb (Fig. 1a), which belongs to the family 
Bignoniaceae, is a popular tree distributed throughout the tropical rain forests of Central 
and South America. T. avellaneda is called “divine tree” by indigenous peoples of South 
America, because it is considered to be one of the most effective, economical and 
versatile remedies against a multitude of acute and chronic diseases for over 1000 
years.
1-4
 Its inner bark (Fig. 1b)is commonly known as “taheebo”, “lapacho”,“pau 
d’arco”, and “ipe roxo”, and it is widely used in local and traditional phytomedicine, 
usually ingested as a decoction to treat numerous conditions like bacterial and fungal 
infections, fever, syphilis, malaria, trypanosomiasis, aswell as stomach and bladder 
disorders.
4,5
 As early as 1873, biomedical uses of Red Lapacho (“Pau D’Arco”) were 
reported.
5
 In 1967 after reports in the Brazilian press it came to the light of clinicians 
(and the public in general).
6,7
 Until now, a variety of studies have been done on T. 




Figure 1  Tabebuia avellanedae (a.) and the inner bark of it (b.) 
(Pictures were from http://orienteocidente.files.wordpress.com, 
http://www.superfoods-for-superhealth.com) 
  
a.                                  b. 
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1.1. Pharmacodynamic and Chemical studies of T. avellanedae 
 
T. avellanedae has been used for various ethnopharmacological purposes. 
Colombians use the bark infusion as stimulant of central nervous system 
7
; Bahamians 
commonly use the bark decoction to prepare an energizing tonic for strength 
7
, and 
Brazilians use this plant to treat malaria, cancer, fever, stomach disorders, bacterial 
and fungal infections and to relief of a variety of mental and emotional states such as 
anxiety, poor memory, irritability and depression 
1,5
. 
Recent pharmacological study indicated that constituents of the bark of this plant 




,  anti-cancer 
10,11
, antinociceptive, anti-emetogenic 
12

















Following its popular use, the chemistry of this plant was extensively studied, 
and a variety of constituents have been isolated, such as furanonaphthoquinones, 
naphtoquinones, quinones, lignans, benzoic acid, cyclopentene dialdehyde, flavonoids, 




1.2.  Anti-cancer research progress of T. avellanedae 
 
T. avellanedae is utilized as a folk remedy for the treatment of cancer 
1,25,26
, and 
its anticancer activity has also been evaluated and confirmed in laboratories 
12,13,22,27
.  
The chemistry of this plant was extensively studied and a variety of constituents 
have been isolated, anticancer properties have been related mainly to the presence of 
naphtoquinones, which also constitute the most prevalent active chemical group in the 
plant. Among the naphtoquinons obtained from the bark of T. avellanedae, lapachol 





. It was reported that lapachol have potent anti-proliferative 
properties against various tumor cell lines 
22,28-30
. However, the phase I clinical trial 
had to be interrupted prematurely due to the prolonged prothrombin time observed 
with doses required for antitumoural activity, which was associated to nausea and 
vomiting 
31
. β-lapachone was proved to have a strong cytotoxic activity in vitro 
against several human and murine cell lines through arresting cell cycle progression 
and inducing apoptosis associated with the down-regulation of the anti-apoptotic 
B-cell lymphoma 2 (BCL-2) and b-cell lymphoma X (BCL-X), up-regulation of the 
pro-apoptotic B-cell lymphoma 2-associated X (BAX) expression, inhibition of 
cyclooxygenase-2 (COX-2) and human telomerase reverse transcriptase (hTERT) 
expression, and proteolytic activation of caspase-3 and -9 
32-35
. However, in the 
following studies, the increased rate of 42% in the duration of survival was observed 
in tumour-bearers treated with the dose of 1 mg/kg while toxicity was evident at 
5mg/g with the death of 33% of treated tumour -bearers in the first 24 h after 
administration 
36
. These negative results reduced the interest on further investigations 
with these compounds.  
The latest studies to find more anticancer compounds from T. avellanedae led to 





But the following studies mainly focused on the 





Further studies should be carried out to find more active 
furanonaphthoquinones as potential candidates of anticancer agents. In addition, 
molecular targets of efficacy, mechanisms of action of them also remain to be 
identified.  
 




The inner bark of T. avellanedae was one of the primary medicines used by the 
Callawaya tribe for over 1000 years. These people used it externally as a poultice or 
concentrated tea for treating a variety of skin inflammatory diseases including eczema, 
psoriasis, and fungal infections, and even skin cancers 
4,22,38-41
. Despite its wide-range 
of pharmacological actions, relatively few studies have investigated the 
anti-inflammatory activity of T. avellanedae inner bark compounds and their effect 
and mechanism in treating inflammatory diseases. It’s reported that prolonged 
intaking of T. avellanedae in arthritic patients reduced arthritis-induced pain and 
edema formation, and restored the morphological abnormality of arthritic joints, and 
the water extract of T. avellanedae may negatively modulate Prostaglandin E2 
(PGE2) mediated inflammatory responses, as it clearly blocked the production of 
PGE2 and nitric oxide (NO), the expression of COX-II and inducible nitric oxide 
synthase (iNOS), and arachidonic acid-induced ear edema via blocking the 
phosphorylation of extracellular signal-regulated kinase (ERK) 
8
. Further study 
proved that iridoids and phenylethanoid glycoside from the water extract of 
T. avellanedae, inhibited NO production in lipopolysaccharide (LPS) activated 
macrophage-like J774.1 cells 
39
, and cyclopentene dialdehydes from T. impetiginosa 
were also reported to have anti-inflammatory activities in the nitro blue teteazolium 




1.4.  Aim of the study 
 
The aim of this study was to discover more bioactive natural product skeletons 
from the inner bark of T. avellanedae as leads to novel agents especially for the 




2. RESULTS AND DISCUSSION 
 
2.1. Compounds isolated from T. avellanedae 
 
In this research, water extract and methanol extract of inner bark of T. avellanedae 
were separated, and 22 new compounds together with 10 known compounds were 
isolated and identified (Scheme 1, Scheme 2, Scheme3). The structures of 1-32 were in 
Figure 2. The 1D NMR data were listed in Table 1 to 13. The 2D NMR correlations 
were shown in Figure 1 to 31. 
 
 
Tabebuia avellanedae  
Extracted 3times with boiling water   
Water extracts of Tabebuia avellanedae 1 
                     Liguid-liquid partition  
                             (Hexane/AcOEt/n-BuOH/H2O) 
 AcOEt Fr. 1 
                                    SiO2 (n-hexane/AcOEt/CHCl3/MeOH) 
 
    Fr. 1                                               Fr. 2    Fr. 3 
        SiO2 (n-hexane/AcOEt/MeOH)              ODS (MeOH/H2O)       
ODS (MeOH/H2O)                      SiO2 (CHCl3/MeOH) 
Sephadex LH-20 (MeOH)             C30 HPLC (MeOH/H2O) 
C30 HPLC (MeOH/H2O)                          
 
4, 5, 6, 29, 30                                     1, 3, 8, 31, 32 
 
Scheme 1  Flowchart 1 of fractionation and isolation of compounds. 






Tabebuia avellanedae  
Extracted 3times with methanol  
Methanol extracts of Tabebuia avellanedae 
                        Liguid-liquid partition (H2O/CHCl3) 
CHCl3 Fr. 
                            SiO2 (n-hexane/AcOEt/CHCl3/MeOH) 
 
 Fr. 1                   Fr. 2                   Fr. 3      
 
SiO2 (n-hexane/AcOEt /MeOH)      SiO2 (n-hexane/AcOEt /MeOH)     SiO2 (n-hexane/AcOEt /MeOH)  
Flash ODS (MeOH/H2O)           ODS (MeOH/H2O)               ODS (MeOH/H2O) 
C30 HPLC (MeOH/H2O)           LH-20 (MeOH)                  LH-20 (MeOH) 
Ph HPLC (MeOH/H2O)            Flash ODS (MeOH/H2O)           Flash ODS (MeOH/H2O) 
                          Flash ODS (MeOH/H2O)           Flash ODS (MeOH/H2O) 
                          C30 HPLC (MeOH/H2O)           Ph HPLC (MeOH/H2O) 
7                       2               9, 10, 11, 12, 13, 14,  
15, 16, 17, 18, 19 
 
Scheme 2  Flowchart 2 of fractionation and isolation of compounds. 







Tabebuia avellanedae  
Extracted 3times with boiling water   
Water extracts of Tabebuia avellanedae 2 
                     Liguid-liquid partition  
                             (n-hexane/AcOEt/n-BuOH/H2O) 
 AcOEt Fr. 2 
                             SiO2 (n-hexane/AcOEt/MeOH) 
                    ODS (MeOH/H2O) 
 
Fr. 1                   Fr. 2                   Fr. 3                 Fr. 4 
ODS (MeOH/H2O)              Sephadex LH-20 (MeOH)               Sephadex LH-20 (MeOH)  
Sephadex LH-20 (MeOH)         C30 HPLC (MeOH/H2O)           SiO2 (n-hexane/AcOEt /MeOH) 
C30 HPLC (MeOH/H2O)                                              ODS HPLC (MeOH/H2O) 
ODS HPLC (MeOH/H2O)                                              C30 HPLC (MeOH/H2O) 
 
26,27                   25                          20, 21, 22, 23, 24, 28 
 
Scheme 3  Flowchart 3 of fractionation and isolation of compounds. 
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Figure 2  Isolated compounds from Tabebuia avellanedae. 






2.2.  Identification of the new compounds  
 
























                      HMBC Correlation            NOE Correlation 
Figure 3  Key HMBC, NOE correlations of 1 
 
Compound 1 was obtained as yellowish solid. Its molecular formula was 
determined as C16H16O5 by HRFABMS m/z 289.1062[M+H]
+
 (calcd. 289.1062 for 
C16H17O5). The 
1
H NMR spectrum of two doublets δH 6.83 (2H, d, J = 8.9) and 7.89 
(2H, d, J = 8.9) and HMBC correlations from δH 6.83 (H-3’ and H-5’) to δC 122.4 (C-1’) 
and 115.2 (C-5’, C-3’), from δH 7.89 (H-2’ and H-6’) to δC 160.0 (C-4’) and 165.9 
(C-7’), suggested the presence of a p-hydroxybenzoate carboxyl group. The 1H and 13C 
NMR spectra and HMQC correlation indicated two aldehyde (δH 9.97, δC 187.0 and δH 
9.77, δC 200.0), in addition, the HMBC correlation from methyl proton δH 2.20 (H-9) to 
δC 45.9 (C-4), δC 137.3 (C-2) and δC 160.7 (C-3), from aldehyde proton δH 9.97 (H-8) to 
δC 45.9 (C-1) and δC 137.3 (C-2), and δH 3.54 (H-1) to δC 77.1 (C-5) and δC 45.9 (C-4) 
suggested the presence of 3-methyl-2-cyclopentene-2-carbaldehyde group with an 
oxidized C-5. Furthermore, HMBC correlations were observed from the other aldehyde 




to δC 45.9 (C-1), δC 137.3 (C-2) and δC 77.1 (C-5), indicated the presence of
 acetaldehyde located at C-1. Moreover, the HMBC correlation from δH 5.14 (H-
5) to δC 165.9 (C-7’) implied that C-5 and C-7’ were connected through an oxy
gen atom. Strong correlations between δH 5.14 (H-5) and δH 3.23 (H-4a), δH 5.14
 (H-5) and δH 3.54 (H-1) and δH 5.14 (H-5), and δH 3.54 (H-1) and δH 2.86 (H-6
a) were observed in the NOE spectrum. Thus, compound 1 was determined as s
hown in Fig. 3.  
 
2.2.2.  4-Hydroxybenzoic acid 2-(2,2-dimethoxyethyl)-3-formyl-4-methylcyclopent-3





























H COSY Correlation         NOE Correlation 




H COSY and NOE correlations of 4 
 
Compound 4 was obtained as brown solid. Its molecular formula was determined 
as C18H22O6 by HREIMS m/z 334.1441 [M]
+
 (calcd. 334.1441 for C18H22O6). The 
characteristics of NMR spectra of compound 4 were very similar to those of compound 
1, indicating that they are based on the same carbon skeleton. However, compound 2 
exhibited only one aldehyde signal and two more methoxy proton [δH 3.30 (3H, s,) and 
δH 3.31 (3H, s,)]. The HMBC correlations from the two methoxy protons δH 3.31 (H-8) 





COSY correlations between δH 4.56 (H-7) and 1.56 (H-6a), δH 2.02 (H-6b) and 3.25 
(H-1), indicated the presence of a 1,1-dimethoxyethane attached to C-1.Thus, compound 
15 
 
4 was determined as shown in Fig. 4. 
 
2.2.3.  4-Methoxybenzoic acid 2-(2,2-dimethoxyethyl)-3-formyl-4-methylcyclopent-3
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H COSY Correlation         NOE Correlation 




H COSY and NOE correlation of 5 
 
Compound 5 was obtained as a brown solid. Its molecular formula was determined 
as C19H24O6 by HRFABMS m/z 371.1451 [M+Na]
+
 (calcd. 371.1451 for C19H24O6 Na). 
The characteristics of NMR spectra of compound 6 are very similar to those of 
compound 4, indicating that they are based on the same carbon skeleton. However, 
compound 5 has one more singlet proton δH 3.83 (H-8’). In addition, the HMBC 
correlation was observed from δH 3.83 (H-8’) to 163.4 (C-4’). Thus, compound 5 was 





2.2.4.  3,4-Dimethoxybenzoic acid 2-(2,2-dimethoxyethyl)-3-formyl-4-methyl-cyclop
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H COSY Correlation         NOE Correlation 




H COSY and NOE correlations of 6 
 
Compound 6 was obtained as a brown solid. Its molecular formula was determined 
as C20H26O7 by HRFABMS m/z 379.1736[M+H]
+
 (calcd. 379.1736 for C20H27O7). The 
characteristics of NMR spectra of compound 6 are very similar to those of compound 4, 
indicating that they are based on the same carbon skeleton. However, 1D spectra and 
HMQC correlations revealed the presence of one ABX system aromatic ring [δH 7.47 (d, 
J = 1.7), 6.84 (d, J = 8.5), 7.59 (dd, J = 1.7, 8.5)] instead of AABB system aromatic ring. 
Furthermore, compound 6 has two singlet protons δH 3.90 (H-8’), δH 3.91 (H-9’), in 
addition, HMBC correlations were observed from H-8’ to 148.6 (C-3’) and H-9’ to 




Table 1 1H-NMR Spectral Data of Compound 1, 4, 5, 6 in CDCl3 
P. 
1
H-NMR [δH (multi,J in Hz)] 
1 4 5 6 
1 3.54 (dd,6.5) 3.25 (d,8.9) 3.26 (d,8.6) 3.28 (d,8.6) 
2 
    
3 
    
4α 3.23 (dd,6.9,20.3) 3.13 (dd,6.2,19.9) 3.14 (dd,6.2,19.9) 3.14 (dd,6.2,19.9) 
4β 2.67 (m) 2.59 (d,19.9) 2.59 (d,19.9) 2.59 (d,19.9) 
5 5.14 (dt,1.7,6.9) 5.32 (d,6.2) 5.33 (d,6.2) 5.32 (d,6.2) 
6α 2.86 (ddd,1.4,4.8,16.8) 1.56 (m) 1.56 (m) 1.56 (m) 
6β 2.67 (m) 2.02 (m) 2.03 (m) 2.05 (m) 
7 9.77 (t,1.5) 4.56 (dd,4.0,6.5) 4.53 (dd,4.0,6.5) 4.51 (dd,4.0,6.5) 
8 9.97 (s) 3.31 (s) 3.31 (s) 3.31 (s) 
9 2.20 (s) 3.30 (s) 3.30 (s) 3.30 (s) 
10 
 
10.00 (s) 10.00 (s) 10.00 (s) 
11 
 
2.18 (s) 2.18 (s) 2.19 (s) 
1’ 
    
2’ 7.89 (d,8.9) 7.89 (d,8.9) 7.92 (d,8.9) 7.47 (d,1.7) 
3’  6.83 (d,8.9) 6.83 (d,8.9) 6.88 (d,8.9) 
 
4’ 
    
5’ 6.83d (8.9) 6.83 (d,8.9) 6.88 (d,8.9) 6.84 (d,8.5) 
6’ 7.89d (8.9) 7.89 (d,8.9) 7.92 (d,8.9) 7.59 (dd,1.7,8.5) 
7’ 
    
8’ 
  
3.83 (s) 3.90 (s) 
9’ 












1  4  5  6  
1 45.9  47.2  47.3  47.2  
2 137.3  138.9  138.9  138.9  
3 160.7  159.5  159.3  159.3  
4α 45.9  46.0  46.0  46.0  
4β 
    
5 77.1  77.0  77.0  77.1  
6α 44.9  33.5  33.6  33.6  
6β 
    
7 200.0  102.8  102.8  102.8  
8 187.0  53.4  53.3  53.3  
9 14.4  51.9  52.0  52.0  
10 
 
187.5  187.5  187.5  
11 
 
14.4  14.4  14.2  
1’ 122.4  122.6  122.6  122.6  
2’ 132.0  161.9  131.6  111.9  
3’  115.2  115.1  113.6  148.6  
4’ 160.0  159.9  163.4  153.0  
5’ 115.2  115.1  113.6  110.1  
6’ 132.0  131.9  131.6  123.6  
7’ 165.9  165.8  122.6  166.0  
8’ 
  
55.4  56.0  
9’ 








































H COSY Correlation 




H COSY correlations of 7 
 
Compound 7 was obtained as a brown solid. Its molecular formula was determined 
as C25H28O7 by HRFABMS m/z 463.1763 [M+Na]
+




C-NMR spectra showed the presence of two AA’BB’ system aromatic 
rings [δH 6.90 (2H, dt, 8.9), 6.93 (2H, dt, 8.9), 7.86 (2H, dt, 8.9), 7.91 (2H, dt, 8.9), and 
δC 114.7, 114.8, 123.6, 123.9, 132.6, 167.8, 167.9]. Furthermore, HMBC correlations 
from 3.34 (H-8’ and H-8”) to 114.8 (C-5’) and 114.9 (C-5”), from δH 7.91 (H-2’ and 
H-6’) to 165.2 (C-4’) and 167.8 (C-7’), from 7.86 (H-2” and H-6”) to 165.1 (C-4”) and 
167.9 (C-7”) indicated the presence of two p-hydroxybenzoate carboxyl groups. In 








H COSY correlations between 
H-4 and H-5, and HMBC correlations from δH 2.93 (H-1), 2.40, 2.93 (H-4), 5.26 (H-5) 








C-NMR Spectral  
Data of Compound 7 in CD3OD
P. 
1D-NMR of 7 
 δH (multi,J in Hz)  δC 







4α 2.40(d,17.8) 44.6 
4β 2.93(overlap) 
 
5 5.26(dt,6.2) 79.5 
6α 1.58(m) 34.8 
6β 1.97(m) 
 
7 3.70(m) 61.3 
8α 4.85(d,12.3) 60.2 
8β 4.99(d,12.3) 
 




2’ 7.91(dt,8.9) 132.6 




5’ 6.93(dt,8.9) 114.8 








2” 7.86(dt,8.9) 132.6 




5” 6.90(dt,8.9) 114.9 




8” 3.34(s) 56.0 
 
 
existence of the cyclopentene skeleton. 
Furthermore, HMBC correlations from δH 
1.36 (H-9) to δC 138.4 (C-2), 132.7 (C-3), 
44.6 (C-4), and from δH 4.85, 4.99 (H-8) 
to δC 52.2 (C-1), 138.4 (C-2), 132.7 (C-3) 
revealed the existence of a methyl group 
attached to C-2 and a methylene group 
attached to C-3. In addition, the HMBC 
correlations from δH 5.26 (H-5) to δC 
167.8 (C-7’) and from δH 4.85, 4.99 (H-8) 
to δC 167.9 (C-7”) indicated the locations 
of the two p-hydroxybenzoate carboxyl 
groups. The mass spectrum suggested the 
presence of one hydroxy group. In 
addition, a down filed shifted carbon 
signal 61.3 (C-7) was observed. Thus, 









2.2.6.  3,4-Dimethoxy-benzoic acid 1,3,7-trihydroxy-7-methyl-octahydro-cyclopent



































H COSY Correlation         NOE Correlation 




H COSY and NOE correlations of 8 
Compound 8 was obtained as a yellowish solid. Its molecular formula was determined 
as C18H24O8 by HRFABMS m/z 391.1244 [M+Na]
+
 (calcd. 391.1244 for 
C18H24O8Na ).  The characteristics of NMR spectra of compound 8 are very similar 
to those of compound 7 
43
 isolated by Garcez F R, except for the signals of the 
substituents located at C-1 and C-3. The signals of δH 5.56, δC 89.7 (C-1), δH 5.02 (H-3) 
and δC 90.8 (C-3) were observed in the NMR spectra of compound 6 instead of 4.96 
(H-1), 97.7 (C-1), 4.78 (H-3) and 97.9 (C-3) in the above paper. No methoxy signal was 
observed in the NMR spectra of compound 6. In addition, the mass data suggested the 
existence of two more hydroxyl groups compare to the compound 7 in the above paper. 
Therefore, two hydroxyl groups, instead of two methoxy, were located at C-1 and C-3. Thus, 





2.2.7.  4-Methoxy-benzoic acid 1,3-dimethoxy-7-methyl-1,3,4,4a,5,6-hexahydro-cy






























H COSY Correlation         NOE Correlation 




H COSY and NOE correlations of 9 
 
Compound 9 was obtained as brown solid. The 
1
H NMR spectrum of two 
doublets δH 6.96 (2H, d, J = 8.9) and 7.94 (2H, d, J = 8.9) and HMBC correlations 
from δH 6.96 (H-3’ and H-5’) to δC 123.6 (C-1’) and 114.8 (C-5’), δH 7.94 (H-2’ and 
H-6’) to δC 165.2 (C-4’) and 167.8 (C-7’), suggested the presence of a 
p-hydroxybenzoate carboxyl group. The HMBC corrections from methyl proton δH 
1.71 (H-10) to δC 44.6 (C-7), δC 133.5 (C-8) and δC 130.5 (C-9) indicated the methyl 




H COSY correlations among δH 2.51, 2.84 (H-7) and δH 
5.10 (H-6), between δH 5.10 (H-6) and δH 3.08 (H-5), and the HMBC correlations 
from δH 3.08 (H-5) to δC 130.5 (C-9), from δH 2.51, 2.84 (H-7) to δC 48.2 (C-5), δC 




H COSY correlations among δH 3.08 (H-5) and δH 2.26, 1.35 (H-4), among δH 
2.26, 1.35 (H-4) and δH 4.80 (H-3), and the HMBC correlations from δH 5.33 (H-1) to 
δC 130.5 (C-9), 133.5 (C-8), δC 48.2 (C-5) and δC 98.2 (C-3), from δH 2.26, 1.35 (H-4) 
to δC 80.4 (C-6), 130.5 (C-9), from δH 3.45 (H-11, H-12) to δC 97.3 (C-1) and δC 98.2 
(C-3) suggested the presence of the 1,3-Dimethoxy-7-methyl-1,3,4,4a,5,6-hexahydro- 
cyclopenta[c]pyran. Furthermore the HMBC correlation from δH 5.10 (H-6) to δC 
167.8 (C-7’) indicated that C-5 and C-7’ was connected through a oxygen atom. Thus 









C-NMR Spectral Data of Compound 8 (in CDCl3) and 9 (in CD3OD) 
P. 
8  9  
δH  (mult, J Hz) δC  δH  (mult, J Hz) δC 





3 5.02 (d,2.4) 90.8   4.80 (dd,10.0,2.1) 98.2  
4α 2.42 (ddd,2.4,10.7,13.7) 34.0   2.26 (ddd,2.1,5.5,12.4) 38.8  
4β 1.72 (dd,2.4,13.7) 
 
 1.35 (dt,10.0,12.4) 
 
5 2.80 (dd,4.8,10.7) 35.9   3.08 (m) 48.2  
6 5.08 (dd,2.4,7.2) 80.1   5.10 (dt,5.5,8.2) 80.4  
7α 1.86 (dd,2.5,15.5) 47.7   2.51 (dd,5.5,16.8) 44.6  
7β 2.62 (dd,7.2,15.5) 
 




79.9   
 
133.5  
9 2.38 (m) 43.3   
 
130.5  
10 1.41(s) 23.3  1.71 (s) 13.4 
11 
  
 3.45 (s) 55.0  
12 
  
 3.45 (s) 56.8  
1’ 
 
123.5   
 
123.6  
2’ 7.49 (d,2.1) 112.0   7.94 (dt,8.9,8.9) 132.6  
3’  
 
148.7   6.96 (dt,8.9,8.9) 114.8  
4’ 
 
153.1   
 
165.2  
5’ 6.86 (d,8.6) 110.2   6.96 (dt,8.9,8.9) 114.8  
6’ 7.61 (dd,2.1,8.6) 123.5   7.94 (dt,8.9,8.9) 132.6  
7’ 
 
166.0   
 
167.8  
8’ 3.91 (s) 56.1   3.83 (s) 56.8  





















































H COSY Correlation 




H COSY correlations of 10 
 
Compound 10 was obtained as a brown solid. Its molecular formula was 
determined as C31H36O13 by HRFABMS m/z 639.2045 [M+Na]
+
 (calcd. 639.205
4 for C31H36O13Na ). The characteristics of NMR spectra of compound 10 are 






C-NMR spectra showed the presence of two AA’BB’
 system aromatic rings [δH 6.96 (2H, dt, 8.9), 6.98 (2H, dt, 8.9), 7.97 (2H, dt,
 8.9), 7.99 (2H, dt, 8.9), and δC 114.7, 114.9, 123.5, 123.8, 132.6, 132.7, 165.
2, 165.3] and a glucose moiety (6 protons between δH 3.00-4.70 ppm and a an
omeric proton at δH 4.71). The downfield shifted proton signal of H-Glc-6 [δH 
4.44 (2H, dd, 5.8, 12.0)] compared with that of the literature
 44
, together with 
HMBC correlation from δH 4.44 (H-Glc-6) to δC 167.8 (C-7”) revealed this is t
he site of gylcosylation. The HMBC correlations from 3.84 (H-8’) to 165.2 (C
-4’), from 3.88 (H-8”) to 165.3 (C-4”) revealed the locations of the methoxy. 
Thus, the structure of 10 was established as in Fig. 10. 
25 
 

















































H COSY Correlation 




H COSY correlations of 11 
 
Compound 11 was obtained as a brown solid. Its molecular formula was 
determined as C32H38O14 by HRFABMS m/z 669.2145 [M+Na]
+
 (calcd. 669.2159 for 
C32H38O14Na ). The characteristics of NMR spectra of compound 11 are very similar 
to those of Compound 10, expect for the signals of one of the aromatic rings. 
1
H-NMR spectrum showed the presence of a AA’BB’ system aromatic ring [δH 6.96 
(2H, dt, 8.9), 7.97 (2H, dt, 8.9)] and a ABX system aromatic ring [δH 7.03 (1H, d, 8.6), 
7.56 (1H, dt, 2.1), 7.69 (1H, dd, 2.1, 8.6)]. HMBC correlations from δH 3.86 (H-8”) to 
150.2 (C-3”) and from δH 3.88 (H-9”) to 154.9 (C-4”) indicated the locations of these 
two methoxy groups. In addtion, HMBC correlation from δH 4.46 (H-Glc-6) to δC 
167.8 (C-7”), indicated ABX system aromatic group was located at C-Glc-6. Thus, the 























































H COSY Correlation 




H COSY correlations of 12 
 
Compound 12 was obtained as a brown solid. Its molecular formula was 
determined as C32H38O14 by HRFABMS m/z 669.2145 [M+Na]
+
 (calcd. 669.2159 for 
C32H38O14Na ). The characteristics of NMR spectra of compound 12 are very similar 
to those of compound 10 and 11, indicating they are based on the same skeleton. 
However, chemical shifts of H-Glc-2, H-Glc-6 in the 
1
H-NMR spectra of 12 were 
different with 10 and 11, indicated the site of glycosylation of 12 was different with 
10 and 11. The downfield shifted H-Glc-2 instead of H-Glc-6 and HMBC correlations 
from δH 4.92 (1H, overlap, 8.9) (H-Glc-2) to δC 167.3 (C-7”) revealed that this was 
the site of glycosylation. HMBC correlations from δH 3.87 (H-8’) to 150.1 (C-3’), 
from δH 3.89 (H-9’) to 154.7 (C-4’) and from δH 3.80 (H-8”) to 165.1 (C-4”) indicated 






















































H COSY Correlation 




H COSY correlations of 13 
 
Compound 13 was obtained as a brown solid. Its molecular formula was 
determined as C31H38O14 by HRFABMS m/z 657.2156 [M+Na]+ (calcd. 657.2159 for 
C31H38O14Na ). The characteristics of NMR spectra of compound 13 are very 
similar to those of compound 10, indicating they are based on the same skeleton. 
However, no downfield shifted proton signal except for H-Glc-1 of was found in the 
1
H-NMR spectra of 13, indicated that aromatic ring was not located at the glucose. 
Furthermore, proton signals of the double bond was not found, insteadly, δH 6.36 
(H-3), δH 1.83, 2.20 (H-4) was observed. In addition, HMBC correlation from δH 6.36 
(H-3) to δC 166.3 (C-7”) was observed, indicated the aromatic group was located at 








H-NMR Spectral Data of Compound 10, 11, 12, 13 in CD3OD 
P. 
1
H-NMR [δH (multi,J in Hz)] 
10 11 12 13 
1 5.30 (d,3.8) 5.29 (d,3.3) 5.48 (d,1.7) 5.54 (d,3.8) 
3 6.23 (dd,6.2) 6.23 (dd,6.2) 5.84 (dd,6.2) 6.36 (dd,3.4,7.2) 
4 5.01 (dd,3.8,6.2) 5.02 (dd,3.1,6.2) 4.42 (dd,6.2) 1.83 (m,7.2,9.6,13.7) 
    
2.20 (m,7.2,9.6,13.7) 
5 2.99 (m) 2.99 (m) 2.63 (d,9.3) 3.00 (m) 
6 4.93 (m) 4.93 (m) 4.87 (overlap) 5.34 (m) 
7 1.97 (dd,3.4,14.4) 1.96 (dd,14.4) 2.00 (dd,14.4) 2.00 (dd,3.4,15.1) 
 
2.18 (dd,6.5,14.4) 2.17 (dd,14.4) 2.15 (dd,14.4) 2.17 (dd,7.2,15.1) 
8 
    
9 2.53 (dd,3.8) 2.52 (dd,3.8) 2.56 (d,9.3) 2.40 (dd,3.8) 
10 1.32 (s) 1.31 (s) 1.32 (s) 1.47 (s) 
Glc 1 4.71 (d,7.9) 4.72 (d,7.9) 4.95 (d,8.2) 4.84 (d,7.9) 
Glc 2 3.23 (m) 3.23 (m) 4.92 (overlap) 3.23 (overlap) 
Glc 3 3.41 (overlap) 3.42 (overlap) 3.70,8.9 (overlap) 3.42 (t,8.9) 
Glc 4 3.43 (overlap) 3.41 (overlap) 3.40 (overlap) 3.28 (overlap) 
Glc 5 3.60 (m) 3.61 (m) 3.40 (overlap) 3.21 (overlap) 
Glc 6 4.44 (dd,5.8,12.0) 4.46 (dd,11.7) 3.71 (overlap) 3.60 (dd,5.8,12.0) 
 
4.63 (dd,2.4,12.0) 4.63 (dd,11.7) 3.96 (d,11.7) 3.74 (dd,2.4,12.0) 
1’ 
    
2’ 7.97 (dt,8.9) 7.97 (dt,8.9) 7.55 (d,2.1) 8.00 (dt,8.9) 




    
5’ 6.96 (dt,8.9) 6.96 (dt,8.9) 7.02 (d,8.6) 6.98 (dt,8.9) 
6’ 7.97 (dt,8.9) 7.97 (dt,8.9) 7.66 (dd,2.1,8.6) 8.00 (dt,8.9) 
7’ 
    






    
2” 7.99 (dt,8.9) 7.56 (d,2.1) 7.95 (dt,8.9) 8.02 (dt,8.9) 
3” 6.98 (dt,8.9) 
 
6.95 (dt,8.9) 7.02 (dt,8.9) 
4” 
    
5” 6.98 (dt,8.9) 7.03 (d,8.6) 6.95 (dt,8.9) 7.02 (dt,8.9) 
6” 7.99 (dt,8.9) 7.69 (dd,2.1,8.6) 7.95 (dt,8.9) 8.02 (dt,8.9) 
7” 
    
















10  11  12  13  
1 93.6 93.6 93.4 94.8 
3 141.2 141.2 140.5 91.7 
4 104.7 104.7 104.9 29.7 
     
5 40.4 40.4 39.1 41.4 
6 80.9  81.0  81.2  80.0  
7 47.4 47.4 48.0  47.8 
     
8 79.4 79.4 78.7 79.4 
9 51.2 51.9 51.5 52.0  
10 26.1 26.1 26.1 27.5 
Glc 1 99.3 99.2 97.3 98.7 
Glc 2 74.8 74.8 75.2 75.1 
Glc 3 77.9 77.9 75.9 78.2 
Glc 4 71.8 71.9 71.8 71.7 
Glc 5 75.7 75.7 78.5 78.2 
Glc 6 64.7 64.8 62.7 62.6 
     
1’ 123.8 123.8 124.0  123.8 
2’ 132.7 132.7 113.5 132.7 
3’  114.7 114.7 150.1 114.8 
4’ 165.2 165.2 154.7 165.3 
5’ 114.7 114.7 111.8 114.8 
6’ 132.7 132.7 125.0  132.7 
7’ 167.7 167.7 167.6 167.8 





1” 123.5 123.6 123.9 123.0  
2” 132.7 113.4 132.9 133.0  
3” 114.9 150.2 114.5 115.0  
4” 165.3 154.9 165.1 165.6 
5” 114.9  112.0  114.5  115.0  
6” 132.7  125.0  132.9  133.0  
7” 167.8 167.8 167.3 166.3 

































































H COSY Correlation 




H COSY correlations of 14 
 
Compound 14 was obtained as a brown solid. Its molecular formula was 
determined as C36H42O17 by HRFABMS m/z 739.2207 [M+Na]
+
 (calcd. 739.739.
2214 for C35H40O16Na ). The characteristics of NMR spectra of compound 14 




H-NMR spectrum of 14 showed the presence of two AA’BB’ system aro
matic ring [δH 6.93 (2H, dt, 8.9), 6.95 (2H, dt, 8.9), 7.94 (2H, dt, 8.9), 7.97 
(2H, dt, 8.9)], HMBC correlations from δH 7.97 (H-2’) to δC 167.7 (C-7’), fro
m δH 4.31 (H-Api-5) to δC 78.6 (C-Api-2), 75.1 (C-Api-4) and 167.7 (C-7’), i
ndicated one aromatic group was located at C-Api-5. In addition, HMBC correl
ations from δH 3.81 (H-8’ and H-8”) to δC 165.3 (C-4’) and 165.2 (C-4”) indi
cated the locations of the methoxy groups. Thus, the structure of 14 was estab






























































H COSY Correlation 




H COSY correlations of 15 
 
Compound 15 was obtained as a brown solid. Its molecular formula was 
determined as C36H40O16 by HRFABMS m/z 769.2330 [M+Na]
+
 (calcd. 769.232
0 for C36H42O17Na). The characteristics of NMR spectra of compound 10 are v




H-NMR spectrum of 15 showed the presence of a ABX system aromatic r
ing [δH 6.93 (1H, d, 8.2), 7.50 (1H, d, 2.1), 7.66 (1H, dd, 2.1, 8.2)]. HMBC 
correlations from δH 3.77 (H-8’) to δC 150.1 (C-3’) and 3.83 (H-9’) to 154.9 
(C-4’) indicated the locations of the methoxy groups. In addition, HMBC corre
lation from δH 7.66 (H-6’) to δC 167.7 (C-7’), from δH 4.31 (H-Api-5) to 78.6
 (C-Api-2) and 167.7 (C-7’) indicated this ABX system aromatic group was lo


































































H COSY Correlation 




H COSY correlations of 16 
 
Compound 16 was obtained as a brown solid. Its molecular formula was 
determined as C37H44O18 by HRFABMS m/z 799.2425 [M+Na]
+
 (calcd. 799.242
5 for C37H44O18Na). The characteristics of NMR spectra of compound 16 are v




H-NMR spectrum of 16 showed the presence of two aromatic protons [δH 
7.31 (4H, s), 6.95 (2H, dt, 8.9), 7.94 (2H, dt, 8.9)]. HMBC correlations from 
δH 3.81 (H-8’and H-10’) to δC 154.4 (C-3’ and C-5’), 3.79 (H-9’) to 143.7 (C
-4’), and from 7.31 (H-2’ or H-6’) to 143.7 (C-4’), 167.3 (C-7’) indicated the 
existence of the 3,4,5 - trimethoxy - benzoyl group. In addition, HMBC correl
ation from δH 4.32 (H-Api-5) to δC 75 (C-Api-4) and 167.3 (C-7’), indicated t
his aromatic group was located at C-Api-5. Thus, the structure of 16 was esta





































































H COSY Correlation 




H COSY correlations of 17 
 
Compound 17 was obtained as a brown solid. Its molecular formula was 
determined as C39H46O18 by HRFABMS m/z 825.2572 [M+Na]
+
 (calcd. 825.2582 for 
C39H46O18Na). The characteristics of NMR spectra of compound 17 are very similar 
to compound 15. However, 
1
H-NMR spectrum of 15 showed the presence of three 
ABX system aromatic rings [δH 6.94 (1H, d, 8.6), δH 6.96 (1H, d, 8.6), δH 7.10 (1H, d, 
8.2), 7.00 (1H, d, 2.1), 7.20 (1H, d, 2.1), 7.52 (1H, d, 2.1), 6.84 (1H, dd, 2.1, 8.2), 
7.14 (1H, dd, 2.1, 8.6), 7.68 (1H, dd, 2.1, 8.6)] and a trans-double bond [δH 6.41 (1H, 
d, 16.2), δH 7.61 (1H, d, 16.2)]. HMBC correlations from δH 3.79 (H-8’) to δC 150.1 
(C-3’), from 3.84 (H-8 and H-10”) to 150.8 (C-2) and 154.4 (C-3”), from 3.85 (H-9’ 
and C-11”) to 154.4 (C-4’) and 152.8 (C-4”), revealed the positions of the methoxy. 
HMBC correlations between 7.20 (H-2”), 7.14 (H-6”) to 146.6 (C-7”), from 6.41 
(H-8”) to 128.8 (C-1”), from 7.61 (H-7”), 5.04 (H-7) to 168.8 (C-9”) indicated the 
existence of a 3 - (3,4 - dimethoxy - phenyl) - propylene carboxyl group located at 































































HMBC Correlation    
Figure 18  Key HMBC correlations of 18 
 
Compound 18 was obtained as a brown solid. Its molecular formula was determined 
as C39H46O18 by HRFABMS m/z 825.2569 [M+Na]
+
 (calcd. 825.2582 for 
C39H46O18Na). The characteristics of NMR spectra of compound 18 are almost the 
same with compound 17, expect for the configuration of the double bond. 
1
H-NMR 
spectrum of 15 showed the presence of a sis-double bond [δH 5.83 (1H, d, 12.7), δH 






H-NMR Spectral Data of Compound 14, 15, 16, 17, 18 in CD3OD 
P. 
δH(multi,J in Hz) 
14 15 16 17 18 
1 
     
2 
     
3 7.04 (d,1.7) 7.01 (d,2.1) 7.03 (d,1.7) 7.00 (d,2.1) 6.90 (d,2.1) 
4 
     
5 6.89 (dd,1.7,8.2) 6.87 (dd,2.1,8.2) 6.88 (dd,1.7,8.2) 6.84 (dd,2.1,8.2) 6.78 (dd,2.1,8.2) 
6 7.12 (d,8.2) 7.10 (d,8.2) 7.10 (d,8.2) 7.10 (d,8.2) 7.06 (d,8.2) 
7 5.14 (s) 5.10 (s) 5.13 (s) 5.04 (s) 4.99 (s) 
8 3.83 (s) 3.81 (s) 3.83 (s) 3.84 (s) 3.77 (s) 
Glc 1 4.84 (d,7.6) 4.83 (d,7.6) 4.82 (d,7.6) 4.82 (d,7.6) 4.82 (d,7.6) 
Glc 2 3.49 (dd,7.6,8.9) 3.50(dd,7.6,9.0) 3.48 (dd,7.6,8.9) 3.49 (dd,7.6,8.9) 3.48 (dd,7.6,8.9) 
Glc 3 3.44 (t,8.9) 3.44 (t,9.0) 3.43 (t,8.9) 3.43 (t,8.9) 3.43 (t,8.9) 
Glc 4 3.32 (overlap) 
3.32 
(overlap,9.0) 
3.29 (overlap) 3.29 (overlap) 3.32 (overlap) 
Glc 5 3.58 (overlap) 3.57 (overlap) 3.57 (overlap) 3.57 (overlap) 3.57 (overlap) 
Glc 6 3.58 (overlap) 3.59 (overlap) 3.60 (overlap) 3.60 (overlap) 3.60 (overlap) 
 
4.04 (d,9.6) 4.01 (d,9.6) 4.02 (d,9.6) 4.03 (d,9.6) 4.03 (d,9.6) 
Api 1 4.99 (d,2.1) 5.00 (d,2.1) 5.00 (d,2.1) 4.99 (d,2.1) 4.99 (overlap) 
Api 2 3.99 (d,2.1) 4.00 (d,2.1) 4.00 (d,2.1) 4.00 (d,2.1) 3.99 (d,2.1) 
Api 4 3.86 (overlap) 3.85 (overlap) 3.84 (overlap) 3.84 (overlap) 3.84 (overlap) 
 
4.04 (overlap) 4.06  (d,9.6) 4.07  (d,9.6) 4.06  (d,9.6) 4.06  (d,9.6) 
Api 5 4.31 (d,11.3) 4.31 (d,11.3) 4.32 (d,11.3) 4.31 (d,11.3) 4.32 (d,11.3) 
 
4.35 (d,11.3) 4.36 (d,11.3) 4.40 (d,11.3) 4.37 (d,11.3) 4.36 (d,11.3) 
1’ 
     
2’ 7.97 (dt,8.9) 7.50 (d,2.1) 7.31 (s) 7.52 (d,2.1) 7.53 (d,2.1) 
3’  6.93 (dt,8.9) 
    
4’ 
     
5’ 6.93 (dt,8.9) 6.93 (d,8.2) 
 
6.96 (d,8.2) 6.97 (d,8.2) 






     
8’ 3.81 (s) 3.77 (s) 3.81 (s) 3.79 (s) 3.80 (s) 
9’ 
 






     
2” 7.94 (dt,8.9) 7.91 (dt,8.9) 7.94 (dt,8.9) 7.20 (d,2.1) 7.51 (d,2.1) 
3” 6.95 (dt,8.9) 6.91 (dt,8.9) 6.95 (dt,8.9) 
  
4” 
     
5” 6.95 (dt,8.9) 6.91 (dt,8.9) 6.95 (dt,8.9) 6.94 (d,8.2) 6.83 (d,8.2) 
6” 7.94 (dt,8.9) 7.91 (dt,8.9) 7.94 (dt,8.9) 7.14 (dd,2.1,8.2) 7.07 (dd,2.1,8.2) 
7” 
   
7.61 (d,16.2) 5.86 (d,12.7) 
8” 3.84 (s) 3.81 (s) 3.83 (s) 6.41(d,16.2) 5.83 (d,12.7) 
9” 
     
10” 
   
3.84 (s) 3.72 (s) 
11” 
   








C-NMR Spectral Data of Compound 14, 15, 16, 17, 18 in CD3OD 
P. 
δC 
14 15 16 17 18 
1 147.9 147.9 147.9 147.8 147.9 
2 150.8 150.7 150.8 150.8 150.7 
3 113.8 113.8 113.8 113.8 113.8 
4 132.6 132.4 132.4 132.1 132.1 
5 122.4 122.3 122.2 122.3 122.4 
6 117.9 117.8 117.8 117.9 117.6 
7 67.5 67.3 67.3 67.1 67 
8 56 55.9 56.7 56.5 56.6 
Glc 1 102.7 102.6 102.6 102.6 102.5 
Glc 2 74.9 74.8 74.8 74.9 74.8 
Glc 3 77.9 77.8 77.9 77.9 77.9 
Glc 4 71.8 71.7 71.8 71.9 71.8 
Glc 5 77 77 77 77 77 
Glc 6 68.8 68.9 69 69 68.9 
Api 1 110.8 110.9 111 111 110.9 
Api 2 78.6 78.6 78.7 78.7 78.6 
Api 3 56 79 78.9 79 79 
Api 4 75.1 75 75 75.1 75.1 
Api 5 67.4 67.5 67.9 67.5 67.5 
1’ 123.2 123.5 126.3 123.4 123.4 
2’ 132.9 113.5 108.2 113.5 113.5 
3’  114.9 150.1 154.4 150.1 150.2 
4’ 165.3 154.9 143.7 154.9 154.9 
5’ 114.9 111.9 154.4 111.9 111.9 
6’ 132.9 125.1 108.2 125.1 125.1 
7’ 167.7 167.6 167.3 167.6 167.6 
8’ 56 56.7 56.7 56.5 56.3 
9’ 
 





1” 123.5 123.4 123.6 128.8 129.2 
2” 132.7 132.6 132.7 111.4 114.5 
3” 114.9 114.8 114.8 150.7 149.6 
4” 165.2 165.1 165.2 152.8 151.6 
5” 114.9 114.8 114.8 112.5 111.9 
6” 132.7 132.6 132.7 124.1 125.8 
7” 167.5 167.7 167.7 146.6 144.4 
8” 56 56.7 56 116.4 117.8 
9” 
   
168.8 168.1 
10” 
   
56.6 56.3 
11” 


























































H COSY Correlation 




H COSY correlations of 19 
 
Compound 19 was obtained as a brown solid. Its molecular formula was 
determined as C34H38O13 by HRFABMS m/z 677.2200 [M+Na]
+
 (calcd. 677.2210 for 
C34H38O13Na). 
1
H-NMR spectrum showed the presence of a AA’BB’ system aromatic 
ring [δH 7.00 (4H, dt, 8.9), 7.97 (2H, dt, 8.9)], two ABX system aromatic rings [δH 
6.96 (1H, d, 8.2), 6.63 (1H, d), 6.62 (1H, d), 6.37 (1H, d), 6.40 (1H, dd) 7.41 (1H, dd)] 
and three methoxy [δH 3.66 (3H, s) , 3.75 (3H, s) and 3.87 (3H, s)]. The six proton 
signals between 3 ppm and 4 ppm and the a anomeric proton signal of δH 4.87 




H COSY spectrum in Fig. 19 revealed the 
connections among C-7, C-8, C-7’, C-8’ and C-9’. HMBC correlations from δH 3.75 
(H-10) to δC 150.5 (C-3), from δH 3.66 (H-9’) to δC 149.0 (C-3’) and from δH 3.87 
(H-8”) to 165.3 (C-4”) indicated the locations of the methoxy groups. In addition, 
HMBC correlations from δH 2.75, 2.83 (H-7), 2.36 (H-8’), 3.94, 4.21 (H-9’), to δC 
181.4 (C-9) revealed the existence of a γ-butyrolactone group. The HMBC 
correlations from the anomeric proton of δH 4.87 to δC 146.5 (C-4), from 4.39 
(H-Glu-6) to δC 167.6 (C-7”), from δH 2.75, 2.83 (H-7) to δC 114.6 (C-2), δC 122.7 
(C-6), and from δH 2.45, 2.52 (H-7’) to δC 113.0 (C-2’), δC 122.3 (C-6’) were 








C-NMR Spectral Data of Compound 19 in CD3OD 
19 
P.  δH (multi,J in Hz)  δC P.  δH (multi,J in Hz)  δC 
1 
 
134.1 Glc 1 4.87 (overlap) 102.4 
2 6.62 (d) 114.6 Glc 2 3.51 (overlap) 77.8 
3 
 
150.5 Glc 3 3.53 (overlap) 74.8 
4 
 
146.5 Glc 4 3.41 (overlap) 72.1 
5 6.96 (d,8.2) 117.4 Glc 5 3.77 (m) 75.5 
6 6.40 (dd) 122.7 Glc 6 4.39 (dd,11.7) 65.1 




1”  123.5 
8 2.59 (m) 47.6 2” 7.97 (dt,8.9) 132.8 
9 
 
181.4 3” 7.00 (dt,8.9) 114.9 
10 3.57 (s) 56.6 4”  165.3 
1’ 
 
131.1 5” 7.00 (dt,8.9) 114.9 
2’ 6.37 (d) 113 6” 7.97 (dt,8.9) 132.8 
3’  
 
149 7”  167.6 
4’ 
 
146.1 8” 3.87 (s) 56.1 
5’ 6.63 (d) 116.1    
6’ 6.41 (dd) 122.3    




   
8’ 2.36 (m) 42.2    




   









































H COSY Correlation         NOE Correlation 




H COSY and NOE correlations of 20 
 
Compound 20 was obtained as colorless oil. Its molecular formula was det
ermined as C20H20O7 by HRFABMS m/z 371.1129 [M-H]-. The 1D NMR spec
tra and HMQC spectrum showed the presence of two ABX system aromatic ri
ngs [δH 6.95 (d, J = 1.7), 6.79 (d, J = 8.5), 6.90 (dd, J = 1.7, 8.5) and 7.03
 (d, J = 1.7), 6.77 (d, J = 8.5), 6.84 (dd, J = 1.7,8.5)], one methylenedioxy g
roup [δH 5.93 (2H, s) and δC 102.4] and one methoxy group [δH 3.86 (3H, s) 
and δC 56.4]; the presence of two doublets [δH 4.04 (d, J = 9.3), 3.84 (d, J =
 9.3) and δC 76.1], and an apparent triplet and a double doublets [δH 4.45 (t, 
J = 8.9), 3.77 (dd, J = 5.8,8.9) and δC 72.0] for nonequivalent geminal methyl
ene protons at C-9' and C-9, respectively, together with one double triplet [δH 
3.00 (dt, J = 5.8, 8.9) and δC 62.6], one doublet [δH 4.84 (d, J = 5.8) and δC
 87.6], and one singlet [δH 4.66 (s) and δC 89.2] suggested a structure of fura
nofuran lignan with two ABX aromatic rings. It has the similar spectra with 
(1S*,2R*,5R*,6S*)-6-(4-hydroxy-3- methoxyphenyl)-2-(3,4-methylenedioxyphenyl)-
3,7-dioxabicyclo[3.3.0]-oactan-1-ol reported by S. Yamauchi et al.,
12
 expect for 
the positions of the two ABX system aromatic rings. In Figure 2, HMBC corr
elations observed from δH 5.93(H-10) to δC 149.4 (C-3), δC 148.7 (C-4), from 
40 
 
δH 6.90 (H-6) to δC 107.8 (C-2), δC 148.7 (C-4) and δC 87.6 (C-7), from δH 6.
95 (H-2) to δC 148.7 (C-4), δC 121.0 (C-6) and δC 87.6 (C-7), together with 1
H-1H COSY correlations between δH 4.84 (H-7) and δH 3.00 (H-8), and amon
g δH 4.45(H-9α), δH 3.77 (H-9β) and δH 3.00 (H-8), supported the methylenedi
oxy-substituted phenyl group is located at C-7 (not C-7') of furanofuran group.
 In addition, the NOE correlations (measured in DMSO) were observed betwee
n H-8 and H-8'-OH, from H-8 to H-9β, from H-7 to H-7'α, and from H-7 to 
H-9α. Thus, the structure of 20 was established as in Fig. 20.  
 





























         HMBC Correlation    
Figure 21  Key HMBC correlations of 21 
 
Compound 21 was obtained as colorless oil. Its molecular formula was 
determined as C20H20O7 by HRESIMS m/z 371.1122 [M-H]
-
. The characteristics of 
the NMR spectra of compound 4  is very similar to that of compound 3, expect for 
the HMBC correlations from H-7 to C-2 and from H-2’ to C-7’, suggested that 
compound 4 has an opposite positions of C-7, C-8, C-9 and C-7’, C-8’, C-9’ with that 







C NMR and 
1
H NMR Spectral Data of Compounds 20 and 21 in CD3OD.  
P. 
20  21 
δH  (mult, J in Hz) δC  δH (mult, J in Hz) δC 
1  136.4   133.5 
2 6.95 (d,1.7) 107.8  6.94 (d,1.4) 109.3 
3   149.4   149.1 
4   148.7   148.9 
5  6.79 (d,8.5) 109.0  6.77 (d,8.2) 116.0 
6 6.90 (dd,1.7,8.5) 121.0  6.87 (dd,1.4,8.2) 122.0 
7 4.84 (d,5.8) 87.6  4.68 (s) 89.1 
8 3.00 (dt,5.8,8.9) 62.6   92.9 
9α 3.77 (dd,5.8,8.9) 72.0  4.02 (d,9.3) 76.1 
9β 4.45 (t,8.9)   3.85 (d,9.3)  
1'  129.0   131.7 
2' 7.03 (d,1.7) 112.7  7.03 (d,1.7) 111.2 
3'  148.7   149.0 
4'   147.5   147.3 
5' 6.77 (d,8.5) 115.7  6.78 (d,8.2) 108.6 
6' 6.84 (dd,1.7,8.5) 121.6  6.85 (dd,1.7,8.2) 120.4 
7' 4.66 (s) 89.2  4.83 (overlap) 87.7 
8'  92.8  3.02 (dt,5.8,8.9) 62.3 
9'α 4.04 (d,9.3) 76.1  3.75 (d,6.2,8.9) 72.0 
9'β 3.84 (d,9.3)   4.44 (t,8.9)  
-OCH3 3.86 (s) 56.3  3.85 (s) 56.39 



























H COSY Correlation   




H COSY and NOE correlations of 22 
 
Compound 27 was obtained as yellow powder. Its molecular formula was 
determined as C14H14O5 by HRFABMS m/z 261.0759 [M-H]-. The 1H NMR 
spectrum of two singlet δH 6.55 (s) and 6.35 (s), and HMBC correlations from δH 
6.55 (H-5) to δC 126.1 (C-8a) and δC 144.7 (C-7), from δH 6.35 (H-8) to δC 126.3 
(C-4a) and δC 145.8 (C-6) suggested the presence of a aromatic ring. The 
1
H NMR 





H COSY correlations between δH 3.96 (H-3α) and δH 2.68(H-4α), from δH 
3.80 (H-3β) to δH 2.72 (H-4β), suggested the presence of one oxidized ethyl group, 
and the HMBC correlations from δH 6.55 (H-5) to δC 28.7 (C-4), from δH 2.72 (H-4β) 
to 126.1 (C-8a), and from δH 3.80 (H-3β) to δC 126.3 (C-4a) indicated that the 
oxidized methylene group is located at C-4a of the aromatic ring. The 
1
H NMR 
spectrum of a singlet at δH 5.66 (s) suggested the presence of one oxidized methine 
group, and the HMBC correlations from δH 5.66 (H-1) to δC 114.0 (C-8) and 126.3 
(C-4a), indicated that the oxidized methine group is located at C-8a of the aromatic 
ring. Furthermore, the HMBC correlations from δH 5.66 (C-1) to δC 63.0 (C-3) 
confirmed the presence of one isochroman group. The 
1
H NMR spectrum of one 
singlet at δH 4.47 (2H, s) revealed the presence of one hydroxymethyl group. The 
remaining signals of two doublet at δH 6.08 (d, J = 3.4) and 6.23 (d, J = 3.4) in the 
1
H 




H COSY correlations between δH 6.08 and δH 6.23 and the 
43 
 
HMBC correlations from δH 6.08 (H-10) to δC 156.3 (C-12), from δH 6.23 (H-11) to 
δC 156.1 (C-9) were noted. Furthermore, its molecular formula was determined as 
C14H14O5, indicated the presence of one furyl group. In addition, the HMBC 
correlations from δH 4.47 (H-13) to δC 108.9 (C-11) proved that the hydroxymethyl 
group is located at the C-12 of the furyl group. The HMBC correlations from δH 5.66 
(H-1) to δC 111.7 (C-10) and 156.1 (C-9), indicted the furyl group is located at C-1 of 




H NMR and 
13
C NMR Spectral Data of Compounds 27 in CD3OD. 
27 
P. δH (mult, J in Hz) δC P. δH (mult, J in Hz) δC 
1 5.66 (s) 72.6 7  144.7 
3α 3.96 (m) 63.0 8 6.35 (s) 114.1 
3β 3.80 (m)  8a  126.1 
4α 2.68 (m) 28.7 9   156.1 
4β 2.72 (m)  10 6.08 (d,3.4) 111.7 
4a  126.3 11 6.23 (d,3.4) 108.9 
5 6.55 (s) 116.0 12  156.3 
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H COSY and NOE correlations of 23 
 
Compound 28 was obtained as yellow amorphous powder. It was synthesized by 
K. Mori and K. Okada in 1984
 46
 but NMR data was not showed. The 1D NMR 
spectra of seven protons [δH 7.49 (m), 7.44 (dd, J = 7.6, 7.9) , 7.86 (d, J = 7.9) , 7.80 
(d, J = 8.3) , 7.55 (m), 7.51 (m), 8.07 (d, J = 8.6) ] and carbon signals [δC 137.7, 126.7, 
125.2, 128.9, 133.2, 128.6, 126.0, 122.6, 123.2, 130.9], suggested the existence of 
more than one aromatic rings. Correlations observed in HMBC spectrum, from δH 
8.07 (H-9') to δC 126.0 (C-7'), δC 133.9 (C-5'a) and δC 137.7(C-2'), from δH 7.51 (H-8') 
to δC 130.9 (C-9'a) and δC 128.6 (C-6'), from δH 7.80 (H-6') to δC 122.6 (C-8'), δC 
130.9 (C-9'a) and δC 128.9 (C-5'), from δH 7.86 (H-5') to δC 128.6 (C-6'), δC 130.9 
(C-9'a) and δC 126.7 (C-3'), from δH 7.44 (H-4') to δC 133.9 (C-5'a) and δC 137.7 
(C-2'), from δH 7.49 (H-3') to δC 128.9 (C-5') and δC 130.9 (C-9'a) revealed presence 
of one naphthyl group. The 1D NMR spectra and HMQC spectrum revealed the 
presence of two methyl groups [δH 1.27 (3H, s), δC 26.9 and 1.68 (3H, d, J = 6.5), δC 
20.7], two methylene groups [δH 2.46 (m), 2.20 (m), δC 46.5, and δH 1.77 (m), 1.64 
(m), δC 42.1], one hydroxymethyl group [δH 3.86 (m), 3.76 (m) and δC 59.6], one 
oxidized quaternary carbon [δC 72.5], one downfield-shifted methine group and one 
carbonyl group [δC 171.2]. Furthermore, the HMBC correlations from δH 1.68 (H-10') 
to δC 137.7 (C-2') and δC 44.6 (C-1') and from δH 7.49 (H-3') to δC 44.6 (C-1') 
revealed C-1' is located at C-2' of naphthyl group. The HMBC correlations from δH 
2.46 (H-2α) to δC 171.2 (C-1), δC 72.5 (C-3) and δC 26.9 (C-6), from δH 1.27 (H-6) to 
δC 46.5 (C-2), δC 72.5 (C-3) and δC 42.1 (C-4) and from δH 3.86 (H-5α), δH 3.76 (H-5β) 
45 
 
to δC 72.5 (C-3) indicated the presence of 3,5-dihydroxy-3-methylpentanyl group. In 
addition, its molecular formula was determined as C18H23NO3 by HRFABMS m/z 
300.1606 [M-H]
-
, confirmed the presence of nitrogen. The NOE correlations from δH 
5.95 (H-1') to δH 8.07 (H-9'), 1.68 (H-10') and 6.17 (-NH-), from δH 2.46 (H-2α), 2.20 
(H-2β) to δH 6.17 (-NH-) and 1.27 (H-6) revealed the imino group is located to C-1' 




H NMR and 
13
C NMR Spectral Data of Compounds 28 in CDCl3. 
28 
P. δH (mult, J in Hz) δC P. δH (mult, J in Hz) δC 
1  171.2 1' 5.95 (m) 44.6 
2α 2.46 (d,15.4) 46.5 2'  137.7 
2β 2.20 (d,15.4)  3' 7.49 (m) 126.7 
3   72.5 4'  7.44 (dd,7.6,7.9) 125.2 
4α 1.77 (m) 42.1 5' 7.86 (d,7.9) 128.9 
4β 1.64 (m)  5'a  133.9 
5α 3.86 (m) 59.6 6' 7.80 (d,8.3) 128.6 
5β 3.76 (m)  7' 7.55 (m) 126.0 
6 1.27(s) 26.9 8' 7.51 (m) 122.6 
-NH- 6.17 (d,7.9)  9' 8.07 (d,8.6) 123.2 
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Figure 24  Key HMBC correlations of 24 
 
Compound 31 was obtained as yellow needles. The IR spectrum showed strong 
absorptions for hydroxy (3450 cm-1) and carbonyl (1645 cm-1) functionalities; and 
it’s UV spectrum, with absorptions at 249 and 296 nm, indicated that it was a 
naphthoquinone derivative 
26,47
. The 13C NMR spectrum showed two carbonyl 
signals at δC 186.5 and 172.6. The 
1
H NMR spectrum in CDCl3 showed proton 
signals at δH 12.15 (1H, s) and 7.72 (1H, dd, J = 0.7; 7.2 Hz), 7.59 (1H, t, J = 7.2; 8.3 
Hz), 7.25 (1H, dd, J = 0.7; 8.3 Hz) and 6.93 (1H, s). The data given above indicate 
that it is furanonaphthoquinone containing a peri-hydroxyl group [3]. The HMBC 
correlations from δH 7.72 (1H, dd, J = 0.7; 7.2 Hz) (H-8) to δC 125.3 (C-6), 115.2 
(C-4a), from δH 7.59 (1H, t, J = 7.2; 8.3 Hz) (H-7) to δC 162.3 (C-5), 131.9 (C-8a), 
from δH 7.25 (1H, dd, J = 0.7; 8.3 Hz) (H-6) to δC 120.0 (C-8), 115.2 (C-4a) 
confirmed the presence of a aromatic ring. The HMBC correlations from δH 12.15 
(1H, s) (-OH) to δC 125.3 (C-6), 115.2 (C-4a), 162.3 (C-5) indicated that the hydroxyl 
group is located at C-5 of the aromatic ring. The 1H NMR spectrum of a singlet at δH 
1.59 (3H, s) and two doublets at δH 4.04 (1H, d, J =11.0 Hz), δH 3.73 (1H, d, J =11.0 
Hz), together with HMBC correlations from δH 1.59 (3H, s) (H-3') to δC 165.9 (C-2), 
72.5 (C-1'), 68.7 (C-2'), from δH 3.73 (1H, d, J =11.0 Hz) (H-2') to δC 165.9 (C-2), 
indicated the presence of 1,2-dihydroxypropyl group. Furthermore, the HMBC 
correlations from δH 6.93 (1H, s) (H-3) to δC 165.9 (C-2), 152.1 (C-9a), from δH 7.72 
(1H, dd, J = 0.7; 7.2 Hz) (H-8) to δC 172.6 (C-9) indicated the structure of compound 
3 (Fig. 1). In addition, its molecular formula which was determined as C15H12O6 by 
47 
 




H NMR and 
13
C NMR Spectral Data of Compounds 31 in CDCl3. 
31 
Position  δH  mult  (J Hz)  δC 
2    165.9 
3  6.93 s  104.7 
3a    132.7 
4    186.5 
4a    115.2 
5    162.3 
6  7.25 dd (0.7, 8.3)  125.3 
7  7.59 dd (7.2, 8.3)  136.3 
8  7.72 dd (0.7, 7.2)  120.0 
8a    131.9 
9    172.6 
9a    152.1 
1'    72.5 
2'α  4.04 d (11.0)  68.7 
2'β  3.73 d (11.0)   
3'  1.59 s  23.6 
5-OH  12.15 s   
 
2.3.  Identification of the known compounds 
  






, epipinoresinol (22) 
48






, salicifoliol (25) 
50













 were identified by comparing their spectroscopic 








2.4.  Furanonaphthoquinones from T. avellanedae induce cell cycle 
arrest and apoptosis in the human non-small cell lung cancer cell line 
A549 
 
2.4.1.  Cytotoxic effects of compounds (29-32) on A549, MCF-7 and SiHa cells 
 
To determine the cytotoxic effects of the compounds (29-32) isolated from T. 
avellanedae, we first evaluated their effects on cell growth of A549, MCF-7 and SiHa 
cells. Results showed that compounds 29, 30 and 31 caused dose-dependent decreases 
in cell viability in all the cell lines; whereas the cells used in this study did not die 
significantly even at the highest concentration (13.5 μM) of compound 32. IC50 values 
(μM) of compounds (29-32) on A549, MCF-7 and SiHa cells assessed by MTT assay 
are presented in Table 14. Furthermore, results indicated that the presence of a 
phenolic hydroxyl group at C-5 seems to play an important role in increasing 




Table14. IC50 (μM) values for compounds (29-32) on A549, 
MCF-7 and SiHa cell lines (mean ± S.D., n=3) 
 
 cell line  
A549 MCF-7 SiHa 
DOX 0.07±0.004 0.62±0.06 0.27±0.01 
29 1.95±0.31 2.97±0.41 3.40±0.60 
30 0.50±0.06 0.89±0.11 1.16±0.32 
31 1.12±0.13 1.89±0.40 2.01±0.40 
32 10.16±0.36 >13.50 >13.50 
 
2.4.2.  Effects of compounds (30, 31) on cell cycle and cell cycle-associated 
proteins. 
 
Cell cycle plays an important part in the processes of cell proliferation and 
growth as well as of cell division. It typically divided into four phases. The period 
50 
 
associated with DNA synthesis (S phase) and mitosis (M phase) are separated by gaps 
of varying length (G1 phase and G2 phase) 
53
. It governs the transition from 
quiescence to cell proliferation, and through its checkpoints, ensures the fidelity of the 
genetic transcript.
 
One of the hallmarks of cancer is the malfunction within the 
regulation of cell cycle, such that injured or mutated cells which are normally killed 
are allowed to progress the cell cycle 
54
. Moreover, unlike normal cells that rely on the 
G1 checkpoint to protect against DNA damage, cancer cells are more dependent on 
the G2 checkpoint for DNA damage repair 
55
. Cell cycle arrest is an important way to 
inhibit the proliferation of cancer cells except for apoptosis, and is considered as a 
potential approach for cancer treatment 
56
. Therefore, cell cycle was evaluated after 
treatment of compounds (30, 31). Fig. 26 showed that exposure of A549 to compound 
30 or compound 31 resulted in significant increased distributions in the G2/M phase 
and S phase accompanied by a decreased distribution in the G1 phase 
time-dependently. The cell percentages of G2/M phase and S phase increased by 
2.5-fold and 2.8-fold, respectively, after 48h treatment of compound 30, and increased 
by 3.3-fold and 1.9-fold, respectively, after 48h treatment of compound 31, while the 
cell percentage of G1 phase decreased by 3.3-fold after 48h treatment of compound 
30 and decreased by 2.5-fold after 48h treatment of compound 31. 
    The cell cycle progression depends on a cascade of enzymes by sequential 
activation and inactivation of cyclins, cyclin-dependent kinases (CDK) and 
cyclin-dependent kinase inhibitors (CDIs) 
57
. The controlled function of these cell 
cycle regulatory proteins is an important means of inhibition of cancer cell growth 
and division 
57
. During late S phase and throughout G2 phase, cells prepare for 
mitosis by increasing levels of cyclins A and B, whereas for cell to exit mitosis, 
cyclins A and B must be degraded 
53,57
. Progression from G1 to S phase in mammalian 
cells is promoted by the accumulation of cyclins D, E and A which bind to and 
activate different CDK catalytic subunits 
57
. Therefore, effects of compounds (30, 31) 
on cell cycle regulatory molecular, including cyclins A, B and D were determined 
subsequently. Fig. 27 showed that the protein expression of cyclin A and cyclin B1 in 
A549 cells was significantly down-regulated after 24 h of exposure and maintained at 
51 
 
an extremely low level after 30 h of exposure. In addition, decreased D1 protein level 





Figure 25. The cell morphology of A549 cells after treatment with compound 31 
12 h. Cont. 





Figure 26. Induction of S and G2/M cell cycle arrest of A549 cells by compounds (29-32) from 
Tabebuia avellanedae (mean ± S.D., n=3). Significance: * p＜0.05 versus the control (0h);  
** p＜0.01 versus the control (0h). 
 
  
























































































Figure 27. Down-regulation of cell cycle-associated protein expression in A549 cells treated with 
compounds (30, 31) from Tabebuia avellanedae (mean ± S.D., n=3). Significance: * p＜0.05 




















































































































































































































2.4.3.  Effects of compounds (30, 31) on apoptosis and apoptotic markers  
 
Apoptosis (programmed cell death) is the essential mechanism in the 
development and homeostasis of multi-cellular organisms to eliminate unwanted cells 
58
. In addition, apoptosis can prevent carcinogenesis by eliminating damaged cell or 
inhibiting abnormal cell development. Therefore, the induction of apoptosis of cancer 
cells plays crucial roles in the anticancer properties of many anticancer agents. We 
invested whether the inhibited cell viability induced by compounds (30, 31) was 
associated with apoptosis via double staining of PI and annexin V-FITC. As shown in 
Fig. 28, compound 30 and compound 31 induced apoptosis in a time-dependent 
manner. The quantitative analysis showed the apoptosis rates (early and late) of 
compound 30 and compound 31 were 17.0% and 5.0% after 36h of treatment, and 
22.8% and 26.6% after 48h of treatment, respectively. 
Apoptosis is controlled by a large number of genes acting as death switches. To 
further elucidate the underlying mechanisms; we then detected some apoptotic 
markers in A549 cells treated with compounds (30, 31). Tumor suppressor P53 plays 
a crucial role in cell cycle progression, DNA repair and apoptosis 
59
. Tumor cells in 
which P53 is inactive can bypass the G1/S checkpoint and fail to arrest and repair 
their damaged DNA 
57
. P53 can also suppress G2/M transition as a primary 
component of the G2 check point. Moreover, P53 can regulate the balance of BCL-2 
family members, which are considered to be the key regulators of apoptosis 
60,61
. The 
BCL-2 family includes both pro-apoptotic (e.g. BAX) as well as anti-apoptotic (e.g. 
BCL-2) molecules, and they seem to spend most of their time simply to block each 
other’s next move. The balance between their competing activities is a major 
checkpoint in the common portion of the mammalian cell death pathway and 
determines cell fate: survival or death.
62
 Downstream of this checkpoint are two major 
execution programs: the caspase pathway and mitochondrial dysfunction. 
Mitochondrial dysfunction includes a change in the mitochondrial membrane 
potential, production of reactive oxygen species, opening of the permeability 
transition pore and the release of the inter-membrane space protein, cytochrome c. 
55 
 
Released cytochrome c activates Apaf-1, which in turn activates a downstream 
caspase program. Activated caspases can also affect the function of mitochondria. 
Caspases could be activated through Apaf-1/cytochrome c or directly by activation of 
cell surface death receptors. 
63
 Caspase activation serves as a final common channel 
for both pathways of apoptosis 
64
. The activated caspase (e.g. caspase-3) cleaves death 
substrates, which ultimately leads to cell death 
65
. Fig. 29 demonstrated that 
compound 30 and compound 31 induced rapid increases in P53 mRNA level from 
about 6-12 h after treatment, followed by apparent up-regulation of BAX at 36 h after 
treatment with no effect on BCL-2. Fig. 30 showed that both compound 30 and 
compound 31 induced the activities of caspase-3 in a time-dependent way.  
In conclusion, compound 30 and compound 31 inhibited the cell viability of all 
three cell lines, with cell cycle arrest at G2/M and S phase through the down- 
regulation of cell cycle dependent proteins such as cyclins A, B1, D1, along with 
induction of apoptosis through the up-regulation of P53 and BAX, and activation of 
caspase-3. These furanonaphthoquinones isolated from T. avellanedae are promising 





Figure 28. Induction of apoptosis of A549 cells by compounds (29-32) from Tabebuia 
avellanedae (mean ± S.D., n=3). Significance: * p＜0.05 versus the control (0h); ** p＜0.01 
versus the control (0h). 
 




























































































Figure 29. Alterations in mRNA expression of apoptosis-related genes P53, BAX and BCL-2 in 
A549 cells treated with compounds (30, 31) from Tabebuia avellanedae (mean ± S.D., n=3). 
Significance: * p＜0.05 versus the control (0h); ** p＜0.01 versus the control (0h). 
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Figure 30. Activation of caspase-3 enzyme of A549 cells by compounds (30, 31) from Tabebuia 
avellanedae (mean ± S.D., n=3). Significance: * p＜0.05 versus the control (0h); ** p＜0.01 













































































2.5.  Compounds from T. avellanedae suppress inflammatory 
productions in the LPS-activated mouse leukaemic monocyte 
macrophage cell line RAW 264.7 as well as on the LPS-activated 
macrophages from BCG infected C3H/HeN mouse 
 
Inflammation is one example of a group of host-defensive mechanisms known as 
innate immunity. This mechanism is an immunological response following bacterial 
and viral infection, and is primarily mediated by phagocytic macrophages, which are a 
type of differentiated tissue cells arising from blood monocytes. The inflammatory 
response involves the activation of several immune cells such as monocytes and 
macrophages which secrete a series of pro-inflammatory mediators such as enzymes, 
cytokines, chemokines as well as signalling proteins at the site of infected tissues and 
cells. During inflammatory responses, numerous intracellular and extracellular signals, 
antigen receptors and pro-inflammatory cytokines activate janus kinase (JAK)/signal 
transducer and activator of transcription (STAT), phosphatidylinositol 3- kinases 
(PI3K)/Akt, mitogen-activated protein kinases3 and nuclear factor-kappa B (NF-kB) 
signaling pathways. 
66-69
 Although these signaling pathways are important to regulate 
physiological functions under normal condition, their aberrant activation is associated 
with a wide range of inflammatory and immune disorders, and cancer.  
68,70,71
 
Therefore, the effective blockade of the production of inflammatory mediators in 
macrophages is regarded as an important therapeutic target. 
Macrophages are known to play a key role in host defense mechanism, and 
activated by exposure to interferon-γ, pro-inflammatory cytokines, and bacterial 
lipopolysaccharides (LPSs). 
72,73
 The favorite model used to study induced 
inflammation both in vitro and in vivo is the stimulation of macrophages by LPS 
obtained from Gram-negative bacteria
74-76
. In case of activation, they become potent 
secretory cells that release a cluster of mediators, including pro-inflammatory and 
cytotoxic cytokines and growth factors, bioactive lipids, hydrolytic enzymes, reactive 
oxygen species (ROS), and nitric oxide (NO), all of which have been implicated in the 
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pathogenesis of tissue injury 
77
. In this research, two kind of LPS-activated 
macrophages were used to investigate the anti-inflammatory effects of compounds 
from T. avellanedae. 
 
2.5.1.  Effects of compounds on inflammatory factors of NO, PGE2 and TNF- α in 
the RAW 264.7 cell line 
 
Inflammation is an essential aspect of the host’s response to infection and injury 
to maintain a healthy state. However, excessive or aberrant inflammation leads to the 
up-regulation of several kinds of pro-inflammatory enzymes such as nitric oxide 
synthase (NOS) and cyclooxygenase (COX) as mediators of inflammation in affected 
inflammatory cells. NOSs are comprised of three members, including endothelial 
NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS), which makes NO 
from L-arginine, and COX exists as two isozymes, COX-1 and COX-2, converting 
arachidonic acid into prostaglandins (PGs). Among them, iNOS and COX-2 are 
highly expressed in response to inflammatory inducers, and are responsible for the 
production of a huge amount of NO and prostaglandin E2 (PGE2), respectively 
78-80
 It 
has been hypothesized that inhibition of excessive NO and PGE2 in macrophages 
could serve as the basis for potential drug development against inflammatory diseases. 
81-83
 The anti-inflammatory properties of compounds were investigated on the RAW 
264.7 cell line. Results showed that LPS triggered macrophage activation and induced 
the rise in the production of inflammatory mediators of NO and PGE2, and all of the 
compounds exclude compound 1 can down-regulate the NO in a dose-dependent 
manner, while all of the compounds exclude compound 3 and 10 can down-regulate 
the PGE2 weakly, and 50 μg/ml of compound 3 and 10 can down-regulate the PGE2 
strongly (Fig. 31, 32).  
The inflammatory response is also well characterized by the abundant production 
of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrotic 
factor-α (TNF-α). They are also mainly produced in activated macrophages by 
inflammatory inducers. In particular, TNF-α exhibited its pro-inflammatory activity 
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by regulating several intercellular and vascular cell-adhesion molecules, resulting in 
the recruitment of leukocytes to sites of inflammation 
84,85
. TNF-α is also important 
for stimulating the secretion of other inflammatory cytokines, which, in turn, causes 
many clinical problems associated with autoimmune disorders 
84,85
. In addition, 
TNF-α is a multi-functional cytokine involved in the signaling pathways implicated in 
inflammation, immunity, cell survival, and even tumorigenesis. Such findings suggest 
that the inhibition of TNF-α production could be a useful approach as a treatment 
strategy for various inflammatory diseases. In the current investigation, the 
concentrations of TNF-α were markedly increased after treatment with LPS in RAW 
264.7 macrophages, but all these compounds used in this research had no effect on the 
TNF-α lever (Fig. 33). In addition, all tested compounds showed no cytotoxic effects 
on RAW 264.7 macrophages (Fig. 34). 
  
2.5.2.  Effects of compounds on inflammatory factors of NO, PGE2 and TNF- α in 
the LPS-activated macrophages from BCG infected mouse. 
 
The activation of murine macrophages by Bacille Calmette Guerin (BCG) has 
been particularly well studied 
86
. The anti-inflammatory properties of compounds 
were also investigated in LPS-activated macrophages from BCG infected mouse. We 
found that LPS triggered macrophage activation and induced the rise in the production 
of inflammatory mediators of NO and PGE2 and TNF-α. In the current investigation, 
all of the compounds exclude compound 1 can down-regulate the NO in a 
dose-dependent manner, and all of the compounds can down-regulate the PGE2 in a 
dose-dependent manner (Fig. 35, 36), but almost all these compounds used in this 
research had no effects on the TNF-α lever (Fig. 37). The 12.5 μg/ml of compound 20 
decreased the lever of TNF-α, but it seems to because of suppression of the cell 
viability (Fig. 32). In addition, 50 μg/ml of 6, 8 and 13 showed cytotoxic effects on 
LPS-activated macrophages from BCG infected mouse (Fig. 38). 
In conclusion, data presented in this research indicated that the tested compounds 
from T. avellanedae may negatively exert a significant anti-inflammatory effect on 
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LPS-mediated inflammatory responses. Most of them significantly blocked the 
production of NO and PGE2 but not TNF-α without altering cell viability (except for 
6, 8, 13 on mcrophages from mouse). From these data, NO production seemed to be 
the most pharmacologically relevant target of T. avellanedae, as the in vitro inhibitory 
potency of them was stronger in NO production than in PGE2 production. These 
results suggest that T. avellanedae’s ethnopharmacological actions (treating 
inflammatory diseases) was based on the constituents which could mediated NO and 
other inflammatory mediators (e.g. PGE2).  
The activation of murine macrophages by Bacille Calmette Guerin (BCG) has 
been particularly well studied 
86
. The anti-inflammatory properties of compounds 
were also investigated in LPS-activated macrophages from BCG infected mouse. We 
found that LPS triggered macrophage activation and induced the rise in the production 
of inflammatory mediators of NO and PGE2 and TNF-α. In the current investigation, 
all of the compounds exclude compound 1 can down-regulate the NO in a 
dose-dependent manner, and all of the compounds can down-regulate the PGE2 in a 
dose-dependent manner (Fig. 35, 36), but almost all these compounds used in this 
research had no effects on the TNF-α lever (Fig. 37). The 12.5 μg/ml of compound 20 
decreased the lever of TNF-α, but it seems to because of suppression of the cell 
viability (Fig. 32). In addition, 50 μg/ml of 6, 8 and 13 showed cytotoxic effects on 












Figure 31. Effect of compounds on the production of NO in LPS-activated RAW264.7 cells (n=3). 









Figure 32. Effect of compounds on the production of PGE2 in LPS-activated RAW264.7 cells 
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Figure 33. Effect of compounds on the production of TNF-α in LPS-activated RAW264.7 cells 









Figure 34. Effect of compounds on RAW264.7 macrophage viability (n=3). *P<0.05, **P<0.01 
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Figure 35. Effect of compounds on the production of NO in the LPS-activated macrophages from 
BCG infected C3H/HeN mouse (n=3). *P<0.05, **P<0.01 represents significant difference 









Figure 36. Effect of compounds on the production of PGE2 in the LPS-activated macrophages 
from BCG infected C3H/HeN mouse (n=3). *P<0.05, **P<0.01 represents significant difference 
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Figure 37. Effect of compounds on the production of TNF-α in the LPS-activated macrophages 
from BCG infected C3H/HeN mouse (n=3). *P<0.05, **P<0.01 represents significant difference 









Figure 38. Effect of compounds on the vialility of macrophages from BCG infected C3H/HeN 
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In this research, 22 new compounds together with 10 known compounds were 
isolated from water extract and methanol extract of inner bark of T. avellanedae, and 
the chemical structures and relative configurations of the new compounds were 
determined by 1D, 2D NMR and MS spectroscopic analyses.  
    A series of furanonaphthoquinones, including a new furanonaphthoquinone and 
four furanonaphthoquinones, based on the naphtho[2,3-b]furan-4,9-dione skeleton 
were obtained from water extract of the inner bark of T. avellanedae. The anti-cancer 
activities of these four furanonaphthoquinones were investigated in this research. 30 
and 31 produced cytotoxicity in A549, SiHa and MCF-7 cells at micromolar 
concentrations. Furthermore, cell cycle analysis was evaluated by PI staining and 
apoptosis was determined by annnexin-V FITC/PI staining using flow cytometry 
analysis, and results showed that 30 and 31 induced cell cycle arrest and apoptosis at 
G2/M phase in A549 cells. Investigation of the cyclin protein family members by 
Western blotting showed that cyclin A and cyclin B protein levels were strongly 
decreased with the increasing time of incubation with 30 and 31, which may be the 
major factor caused G2/M phase arrest. Reverse transcription polymerase chain 
reaction (RT-PCR) analysis demonstrated that following the exposure of A549 cells to 
30 and 31, the level of mRNA expressions of tumor suppressor P53 and apoptotic 
protein BAX were down-regulated. And the caspase-3 enzyme activity was also 
higher in 30 and 31 exposed A549 cells. Therefore, these furanonaphthoquinones 
isolated from T. avellanedae are promising leads for potential anticancer drugs. 
The anti-inflammatory effects of compounds from T. avellanedae were also 
investigated in this research. Effects of compounds (1, 3, 5, 6, 8, 9, 10, 11, 12, 13) on 
inflammatory factors of NO, PGE2 and TNF- α were determined on two kind of 
LPS-activated macrophages, including RAW264.7 macrophages and macrophages 
from BCG infected C3H/HeN mouse. Data presented in this research indicated that 
the tested compounds from T. avellanedae may negatively exert a significant 
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anti-inflammatory effect on LPS-mediated inflammatory responses. Most of them 
significantly blocked the production of NO and PGE2 but not TNF-α without altering 
cell viability (except for high dose of 6, 8, 13 on mcrophages from mouse). From 
these data, NO production seemed to be the most pharmacologically relevant target of 
T. avellanedae, as the in vitro inhibitory potency of them was stronger in NO 
production than in PGE2 production. These results suggest that T. avellanedae’s 
ethnopharmacological actions (treating inflammatory diseases) was based on the 







4. METERIMALS AND METHODS 
 
4.1.  Cell cycle and Apoptosis  
 
4.1.1.  Reagents and antibodies  
 
Dulbecco’s Modified Eagle’s Medium (DMEM), doxorubicin(DOX), MTT, and 
Propidium iodide (PI) were bought from Sigma-Aldrich (USA); FBS was purchased 
from Nichirei Biosciences (Japan); Penicillin Streptomycin was bought from Gibco 
(USA); RNase A and Phosphate Buffered Salts (PBS) were bought from Takara 
(Japan); Annexin V-FITC kit system for detection of apoptosis was purchased from 
Beckman Coulter (France); Coomassie (Bradford) protein assay kit was purchased 
from Thermo scientific (USA); cOmplete EDTA free tablet was bought from Roche 
Applied Science (Germany); Anti-Cyclin A, Anti-Cyclin B1, Anti-Cyclin D1, 
Anti-beta Actin rabbit polyclonal antibody and Goat anti-rabbit IgG HRP-conjugated 
antibody were purchased from Abcam (UK); Western ECL substrate kit was obtained 
from BIO-RAD (Australia); Protein ladder was purchased from Fermentas Life 
Sciences (Canada); Polyvinylidene fluoride (PVDF) membranes were from Millipore 
Corporation (USA); RNeasy mini kit was purchased from QIAGEN (Germany); 
Primers were bought from Eurofins MWG Operon (USA); SuperScript Ⅲ first-strand 
synthesis system and Tracklt 100 bp DNA ladder for RT-PCR were purchased from 
Invitrogen Life Technologies (USA); Takara Ex Taq was bought from Takara (Japan); 
Anti-human Fas antibody was from Medical and Biological Laboratories Co., Ltd, 
(Japan); CaspACE assay system colorimetric kit was bought from Promega (USA). 
Organic solvents and other chemicals were of the highest analytical grade.   
 
4.1.2.  Cell lines and Cell culture  
 
Human lung carcinoma cell line (A549), human cervical carcinoma cell line 
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(SiHa), human breast adenocarcinoma cell line (MCF-7) were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA, USA). All the cell lines 
were maintained in the DMEM medium supplemented with 10% fetal bovine serum, 
100 units/ml penicillin and 100 ug/ml streptomycin. Cells were kept at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2, and maintained in exponential and 
asynchronous phase of growth by repeated trypsinization and reseeding prior to 
reaching subconfluency.  
 
4.1.3.  Cell viability assay (MTT) 
 
Cell viability was assessed by3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazo
lium bromide (MTT) assays to determine IC50 of the studied compounds (29, 3
0, 31, 32). A549 (4×10
3
 cells/ml), SiHa (6×10
3
 cells/ml), MCF-7 (2×10
4
 cells/
ml) were incubated in 96-well microtiter plates for 24 h. Following the additio
n of 0.5 μM, 1.5 μM, 4.5 μM, 13.5 μM of test compounds (29, 30, 31, 32), 
doxorubicin or only medium, the plates were incubated for an additional 72 h.
 Three replicate wells were used at each point in the experiments. After incub
ation, medium was abandoned and 100 μl of MTT solution (final concentration
 0.5 mg/ml, freshly diluted in DMEM immediately before treatment) was adde
d and incubated for another 4 h. The formazan product was dissolved in 150 
μl of stop solution (SDS 40 g, 0.01 N HCl 200 ml, DMF 200 ml) for 18 h t
o solubilize the formazan. The amount of formazan was determined by measuri
ng the absorbance at 570 nm with a microplate reader (BioTek, Japan). The I
C50 values of the samples were determined using IDBS XL fit5.  
 




 cells/ml) was seeded in 6 cm petri dishes and allowed to attach for 
24 h, and then treated with 4.0 μM of compound 29, 1.0 μM of compound 30, 2.2 μM 
of compound 31 or 20.0 μM of compound 32 for 12 h, 24 h, 36 h and 48 h. Prepare 
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negative controls using untreated cells. Cells were collected (including attached and 
detached cells) after incubation, washed with ice-cold PBS and fixed with -20℃ 70% 
ethanol and kept at -20 ℃ overnight. Cells were washed twice with PBS and 
incubated in 1ml PBS containing 200 μg/ml RNase A at 37 ℃ for 30 min. After 
further centrifugation, cells were resuspended in 1 ml of PBS containing 250 μg/ml of 
PI and incubated for 15 min. The percentage of cell distribution was determined using 
a BD FACSVerse flow cytometer (Becton Dickinson, San Jose, CA). At least 10,000 
cells were used for each analysis. Data expressed as the mean of three independent 
experiments. 
 
4.1.5.  Apoptosis analysis 
 
Cells were treated as above. After incubation, cells were harvested (including 
attached and detached cells) washed by ice-cold PBS and the magnitude of apoptosis 
was determined using an Annexin V-FITC kit system according to the manufacturer’s 
protocol. Apoptosis was analyzed by a BD FACSVerse flow cytometer. At least 
10,000 cells were used for each analysis. Data expressed as the mean of three 
independent experiments. 
 




 cells/ml) was seeded in 6cm petri dishes and allowed to attach for 
24 h, and then treated with 1.0 μM of compound 30 or 2.2 μM of compound 31 for 6 
h, 12 h, 18 h, 30 h and 36 h. Prepare negative controls using untreated cells. After 
incubation, cells were lysed and protein concentration was determined using a 
Bradford assay. An equal amount of protein (20 μg) was separated by 10% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using AE-6530 
mPAGE system (Atto, Japan), and resolved proteins transferred to a 0.45 mm PVDF 
membrane via Hoefer Semiphor TE 70 semi-dry blotting apparatus (Amersham 
Biosciences Corp., USA). Blots were probed with a 1:1000 dilution of the desired 
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primary antibody overnight at 4℃, incubated with a 1:10000 diluted secondary 
antibody, visualized by ECL Western Blotting Detection System and images were 
captured by Image Quant LAS 4000 (Fujifilm, Japan). The density of each band was 
measured using Multi Gauge ver. 3.2 (Fuji Film, Japan). The densitometry readings of 
the bands were normalized to β-actin expression. Data expressed as the mean of three 
independent experiments. 
 
4.1.7.  RT-PCR 
 
Cells were treated as above. After incubation, total RNA was extracted by 
RNeasy mini kit according to the manufacturer’s instructions. Concentration of the 
extracted RNA was determined using BioSpec-nano Spectrophotometer (Shimadzu 
Biotech., Japan) and quality was determined by agarose gel electrophoresis using 
Mupid-2 Plus submarine electrophoresis system (Advance, Japan). The first strand c 
DNA was synthesized from 1 μg of total RNA by the SuperScript Ⅲ first-strand 
synthesis system according to the manufacturer’s protocol. RT-PCR was performed 
by Takara Ex Taq kit with specific primers using Arktik thermal cycler (thermo 
scientific, USA). The sequences of the specific sets of the primer used in this study 
are given as in table 2. RT-PCR products were collected after 35 cycles (P53, BCL-2, 
β-actin) or 40 cycles (BAX) and separated in 1.5% agarose gels containing ethidium 
bromide and images were captured by Image Quant LAS 4000. Densitometric 
analysis of bands was done by Multi Gauge ver. 3.2. Expressions of selected genes 
were normalized to β-actin gene, which was used as an internal housekeeping control. 
Data expressed as the mean of three independent experiments. 
 
 




 cells/ml) was seeded in 6 cm petri dishes and allowed to attach for 
24 h, and then treated with 1.0 μM of compound 30 or 2.2 μM of compound 31 for 12 
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h, 24 h, 36 h and 48 h, or treated with 250 ng/ml of anti-Fas antibody (induce 
apoptosis) for 24 h for a positive control. Prepare negative controls using untreated 
cells. After incubation, cells were washed with PBS and extracted in 100 μl of cell 
lysis buffer. Protein extracts (50 μg) were taken for caspase-3 activity measurements 
according to the protocols of CaspACE assay system kit. Reactions were incubated 
overnight at room temperature and free product pNA was monitored by a microplate 
reader at 405 nm. All procedures were performed three times. 
 
4.1.9.  Statistical Analysis 
 
All data were processed and analyzed by KaleidaGraph version 3.6 (Synergy 
Software). Results are expressed as the mean ± standard deviation (S.D.). The 
statistical significances were evaluated by t-test of the software and p＜0.05 was 
considered to be significant.   
 
4.2.  Anti-inflammation 
 
4.2.1.  Reagents  
 
Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI-1640 Medium, MTT 
and Propidium iodide (PI) were bought from Sigma-Aldrich (USA); FBS was 
purchased from Nichirei Biosciences (Japan); Penicillin Streptomycin was bought 
from Gibco (USA); Phosphate Buffered Salts (PBS) were bought from Takara (Japan); 
Griess Reagent System kit was purchased from Promega (USA). Prostaglandin E2 
Parameter Assay Kit was from R&D Systems (USA). Mouse TNF-α ELISA 
Ready-SET-Go kit was from eBioscience (CA). Freeze-Dried BCG Vaccine was from 
Japan BCG Laboratory (Japan). Organic solvents and other chemicals were of the 





4.2.2.  Mice, cell lines, cell culture and treatment  
 
Mouse leukaemic monocyte macrophage cell line (RAW264.7) was obtaine
d from the American Type Culture Collection (ATCC; Manassas, VA, USA). I
t was maintained in the DMEM medium supplemented with 10% fetal bovine 
serum. Cells were kept at 37 °C in a humidified atmosphere of 95% air and  
5% CO2, and maintained in exponential and asynchronous phase of growth by 
repeated dislodging cells from the flask substrate with a cell scraper and resee
ding prior to reaching subconfluency. RAW264.7 (5×105 cells/ml) were seeded 
in 96-well plates and allowed 24 hours to attach. Following the addition of LP
S (final concentration: 250ng/ml) and 12.5, 25, 50 μg/ml of compounds (1, 3, 
5, 6, 8, 9, 10, 11, 12, 13), 0.78, 3.13, 12.5 μg/ml of compound 20 or only m
edium, the plates were incubated for an additional 24 h. After that, cell culture
 supernatants were collected and analyzed for NO, PGE2 and TNF-α productio
n, and the adherent cells were washed and checked for cell viability. 
Male 4-week-old C3H/HeN Slc (SPF) mice were obtained from Sankyo 
Laboratory Service Co. (Japan). 1mg/mouse/200 μl of BCG was injected into 
C3H/HeN Slc mice. After 4 days, mice were decapitated and 4cc of cold RPMI-1640 
was injected through the exposed peritoneum and withdrawn with a no. 25 needle for 
three times. Collected cells were washed by RPMI-1640 at 1400 rpm, resuspended in 
RPMI-1640 containing 5% FBS, seeded in 96-well plates at 5×105 cell/ml (160 
μl/well). After 12 h, non-adherent cells were aspirated with a capillary pipette 
attached to wall suction, and 160 μl of RPMI-1640 containing 5% FBS was added. 
After an additional 12 h, cells were treated with LPS (final concentration: 250ng/ml) 
and 12.5, 25, 50 μg/ml of compounds (1, 3, 5, 6, 8, 9, 10, 11, 12, 13), 0.78, 3.13, 12.5 
μg/ml of compound 20 or only medium. After 48h of incubation, cell culture 
supernatants were collected and analyzed for NO, PGE2 and TNF-α production, and 




4.2.3.  Cell viability assay (MTT) 
 
Three replicate wells were used at each point in the experiments. After 
incubation, the cell culture supernatants were collected, the adherent cells were 
washed and 100 μl of MTT solution (final concentration 0.5 mg/ml, freshly diluted in 
DMEM immediately before treatment) was added and incubated for another 4 h. The 
formazan product was dissolved in 150 μl of stop solution (SDS 40 g, 0.01 N HCl 200 
ml, DMF 200 ml) for 18 h to solubilize the formazan. The amount of formazan was 
determined by measuring the absorbance at 570 nm with a microplate reader (BioTek, 
Japan).  
 
4.2.4.  NO, PGE2 and TNF-α determination  
 
Three replicate wells were used at each point in the experiments. The cell culture 
supernatants were collected after incubation, NO was assessed by the Promega Griess 
Reagent System, according to the manufacturer’s instructions; PGE2 was determined 
using a R&D Prostaglandin E2 Parameter Assay Kit, according to the manufacturer’s 
instructions; TNF-α was quantified using an ELISA kit, according to the 
manufacturer’s instructions. 
 
4.2.5.  Statistical Analysis 
 
All data were processed and analyzed by KaleidaGraph version 3.6 (Synergy 
Software). Results are expressed as the mean ± standard deviation (S.D.). The 
statistical significances were evaluated by t-test of the software and p＜0.05 was 




4.3.  Extraction, Separation and Isolation  
 
4.3.1  General experiment procedures  
 
Optical rotations were measured using a SEPA-3000 high-sensitivity polarimeter 
(Horiba, Japan). UV spectra were measured using a UV-1600 UV-visible spectrometer 
(Shimadzu, Japan). IR spectra were recorded on a IR-460 IR spectrophotometer 
(Shimadzu, Japan), whereas NMR spectra were obtained using the JEOL ECA-600 
NMR spectrometer (JEOL, Japan) in CDCl3. Chemical shifts were referenced to the 
residual solvent peaks (δH 7.24 and δC 77.0 for CDCl3). The mass spectra were 
recorded on a JEOL JMS-700 mass spectrometer (JEOL, Japan) or JEOL JMS 
SX-102 (JEOL, Japan). Reversed-phase HPLC was carried out on C30-UG-5 (5 µm, 
Nomura Chemical, Japan), C18-AR-Ⅱ (5 µm, Nacalai Tesque., Japan). Silica gel 
(63-210 μm, Kantou Kagaku, Japan), ODS (63-212 μm, Wako Pure Chemical, Japan) 
and Sephadex LH-20. (Pharmacia Biotech AB, Uppsala, Sweden) were used for 
open-column chromatography. Thin-layer chromatography (TLC) was carried out on 
silica gel 60 F254 and RP-18 F254S (Merck Co., Germany). 
 
4.3.2. Plant material 
 
    Inner bark of T. avellanedae and Water extract of inner bark of T. avellanedae for 
the present investigation was for the present investigation was taxonomically 
identified and extracted by Taheebo Japan Corporation.  
 
4.3.3. Extraction and isolation 
 
4.3.3.1 Extraction and isolation 1 
 
   Water extract of inner bark of T. avellanedae for the present investigation was 
taxonomically identified and extracted by Taheebo Japan Corporation. In accordance 
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with their method, dried bark of T. avellanedae (10 kg) were extracted with boiling 
water (30 L) three times, and the water solutions were combined and concentrated in 
vacuo to get the crude extract. The water extract (350 g) was suspended in H2O (3.5 L) 
and partitioned successively with n-hexane, EtOAc and n-BuOH (each 3.5 L, 3 times) 
to yield n-hexane fraction (2.3 g), EtOAc fraction (48.6 g), n-BuOH fraction (103.7 g) 
and H2O fraction (190.0 g), respectively. The EtOAc fraction (47.0g) was 
chromatographed on silica gel with a gradient solvent system (n-hexane/EtOAc 3:2, 
CHCl3/MeOH 50:1, 20:1, 10:1) to give 3 fractions (A1-A3). Fraction A1-3 (n-hexane 
/EtOAc =3/2, 1.3 g) was rechromatographed on ODS with gradient solvent (MeOH/ 
H2O) to afford 11 fractions (B1-B11). Fraction B7 (MeOH/H2O 3:4, 79.8mg) was 
subjected on sephadex LH-20 with MeOH to afford 5 fractions (C1-C5). Fraction C4 
(40.0 mg) was further purified by ODS HPLC (C18-AR-Ⅱ) with 57% MeOH to afford 
compound 29 (1.6 mg) and compound 30 (2.2 mg). Fractions B 9 and B 10 
(MeOH/H2O= 1/1, 70.5 mg) was rechromatographed on silica gel with a gradient 
solvent system (CHCl3, CHCl3/MeOH) to give 8 fractions (D1-D6). Fraction D1 
(CHCl3, 22 mg) was separated using C30 HPLC (C30-UG-5) with 33% MeOH to 
afford compound 5 (2.1 mg) and compound 6 (1.7 mg). Fraction D5 (CHCl3/MeOH 
20:1, 113.7 mg) was separated using C30 HPLC (C30-UG-5) with 50% MeOH to 
afford compound 4 (0.9 mg). Fraction A2 (CHCl3/MeOH 50:1, 3.4 g) was 
rechromatographed on silica gel with a gradient solvent system (n-hexane/EtOAc) to 
give 3 fractions (E1-E3). Fraction E2 (n-hexane/EtOAc 1:1, 1.3 g) was 
rechromatographed on ODS with gradient solvent (MeOH/ H2O) to afford 8 fractions 
(E1-E8). E7 (MeOH/H2O 2:1, 175 mg) was subjected on Sephadex LH-20 with 
MeOH to get 7 fractions (F1-F7). Fraction F3 (79.7 mg) was separated using C30 
HPLC (C30-UG-5) with 50% MeOH to afford compound 1 (2.5 mg), compound 3 (1.2 
mg) and compound 8 (1.7 mg). Fraction F4 (73.7 mg) was separated using C30 HPLC 
(C30-UG-5) with 52% MeOH to afford compound 31 (1.3 mg) and compound 32 (1.3 
mg).  
 




Inner bark of T. avellanedae (8.0 kg) for the present investigation was extracted 3 
times by methanol to afford 1.8 kg of MeOH extract. The MeOH extract (1.8 kg) was 
suspended in H2O (1 8 L) and partitioned with CHCl3 (each 18 L, 3 times) to yield 
CHCl3 fraction (240 g) and H2O fraction (1.5 kg). CHCl3 fraction was 
chromatographed on silica gel with a gradient solvent system (n-hexane/EtOAc/ 
CHCl3 /MeOH) to give 3 fractions (A1-A3). A1 (n-hexane /EtOAc =1/1, 138 g) was 
rechromatographed on silica gel with a gradient solvent system (n-hexane/EtOAc= 
9:1、8:2、7:3、6:4、5:5、4:6、3:7、2:8、1:9、0:1) to give 10 fractions (B1-B10). Fractions 
B10  (n-hexane/EtOAc= 1:9) was rechromatographed on ODS with gradient solvent 
(60%、70%、80%、90%、100% of MeOH) to afford 5 fractions (C1-C5). Fractions C2 
(70% MeOH) was separated using C-30 HPLC (C30-UG-5) with 75% MeOH and 
Phenyl HPLC with 75% MeOH to afford compound 7 (1.2 mg). A21 (EtOAc, 53.8 g) 
was rechromatographed on silica gel with a gradient solvent system 
(n-hexane/EtOAc= 1:1、2:3、3:7、3:4、1:4、1:9) to give 6 fractions (D1-D6). Fractions 
D2 (n-hexane/EtOAc= 2:3) was rechromatographed on ODS with gradient solvent 
(20%、40%、60%、80%、100% of MeOH) to afford 5 fractions (E1-E5). Fractions E2  
(40% MeOH) was rechromatographed on LH-20 and then Flash ODS with gradient 
solvent (40%、50%、60%、70%、100% of MeOH) to afford 5 fractions (F1-F5). 
Fractions F3 (60% MeOH) was separated using ODS HPLC (C18-AR-Ⅱ) with 65% 
MeOH and C-30 HPLC (C30-UG-5) with 60% MeOH to afford compound 2 (3.5 mg). 
A21 (CHCl3 /MeOH =1/1, 45.4 g) was rechromatographed on silica gel with a 
gradient solvent system (CHCl3 /MeOH = 1:0、9:1、8:2、7:3、6:4、0:1) to give 6 
fractions (G1-G6). Fractions G2 (CHCl3 /MeOH = 9:1) was rechromatographed on 
ODS with gradient solvent (20%、40%、60%、80%、100% of MeOH) to afford 5 
fractions (H1-H5). Fractions H4 (40% MeOH) was rechromatographed on LH-20 and 
then Flash ODS with gradient solvent (40%、50%、60%、70%、100% of MeOH) to 
afford 5 fractions (I1-I5). Fractions I3 (60% MeOH) was separated using C-30 HPLC 
(C30-UG-5) with 65% MeOH and Phenyl HPLC with 65% MeOH to afford compound 
11 (2.8 mg), 15 (26.8 mg), 17 (1.8 mg), 18 (0.9 mg), 19 (6.9 mg) and separated using 
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Phenyl HPLC with 65% MeOH to afford compound 10 (7.8 mg), 12 (3.5 mg), 13 (4.2 
mg), 14 (3.5 mg), 16 (2.0 mg).  
 
4.3.3.3 Extraction and isolation 3 
 
Dried bark of T. avellanedae (10 kg) were extracted with boiling water (30 L) 
three times. The water solutions were combined and concentrated in vacuo, and the 
residue (100 g) was suspended in H2O (1 L) and partitioned successively with 
n-hexane, EtOAc and n-BuOH (each 1 L, 3times) to yield n-hexane fraction (0.57 g), 
EtOAc fraction (14.13 g), n-BuOH fraction (31.47 g) and H2O fraction (65.13 g), 
respectively. The EtOAc fraction (14g) was chromatographed on silica gel with a 
gradient solvent system (Hexane/EtOAc/MeOH) to give 15 fractions (A1-A15). A3 
and A4 (Hexane/EtOAc =1/1, 2.3 g) was rechromatographed on ODS with gradient 
solvent (MeOH/ H2O) to afford 14 subfractions (B1-B14). B1 (MeOH/H2O= 0/1, 
280mg) was subjected on ODS with gradient solvent (MeOH/ H2O) to afford 12 
subfractions (C1-C12). C7 (MeOH/H2O= 1/4, 6.2 mg) was further separated by 
separative HPLC, ODS column (C18-AR-Ⅱ) with 33% MeOH to afford compound 
27 (6.0 mg). B4 (MeOH/H2O= 1/4, 69 mg) was subjected on Sephadex-LH20 with 
MeOH to get 9 subfractions(D1-D9). D6 was further separated by separative HPLC, 
ODS column (C18-AR-Ⅱ) with 20% MeOH to afford compound 26 (6.0 mg). B5 
(MeOH/H2O= 1/4, 119.2 mg) was subjected on Sephadex-LH20 with MeOH to get 3 
subfractions (E1-E3), and E3 was further separated by separative HPLC, ODS column 
(C30-UG-5) with 40% MeOH to afford compound 25 (2.9 mg).B11 and B12 
(MeOH/H2O= 3/4, 79.8 mg) was subjected on Sephadex-LH20 with MeOH to get 6 
subfractions(F1-F6), and F4(40 mg) was subjected on silica gel with a gradient 
solvent system (CHCl3/MeOH) to give 11 fractions (G1-G11). G4 (6.9 mg) was 
further separated by separative HPLC, ODS column (C18-AR-Ⅱ) with 50% MeOH 
and 55% MeOH to afford compound 23 (0.9 mg) and 20 (1.6 mg) and subfraction H. 
Subfraction H (1.8 mg)  was further separated by separative HPLC, ODS column 
(C30-UG-5) with 52% MeOH to afford compound 22 (1.0 mg) and compound 21 (0.6 
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mg). G6 and G7 (3 mg) was further separated by separative HPLC, ODS column 
(C30-UG-5) with 50% MeOH to afford compound 24 (1.2 mg). B13(MeOH/H2O= 
3/4, 100.9 mg) was subjected on Sephadex-LH20 with MeOH to get 6 
subfractions(I1-I6), and I3 and I4 (85 mg) was subjected on silica gel with a gradient 
solvent system (Hexane/EtOAc) to give 10 fractions (J1-J10). J9 (21.2 mg) was 
further separated by separative HPLC, ODS column (C18-AR-Ⅱ) with 60% MeOH to 





Compound 1.  
Yellowish oil:  α  
     -18.65 (MeOH, c1.00); UV (MeOH) λmax (log ε) 255 (2.72), 
206 (2.77) nm; IR υmax (KBr) 3311, 2920, 2830 1705, 1660, 1608, 1593, 1514, 1444, 




H NMR spectroscopic data (600 MHz, 
CDCl3) and 
13
C NMR spectroscopic data (125 MHz, CDCl3) are shown in Table 1 
and Table 2. HRFABMS m/z 289.1062[M+H]+ (calcd. 289.1062 for C16H17O5). 
 
Compound 4.  
Brown solid:  α  
     6.79 (MeOH, c1.00); UV (MeOH) λmax (log ε) 251 (3.05), 212 
(3.03) nm; IR υmax (KBr) 3300, 2925, 2820, 1705, 1652, 1608, 1593, 1515, 1456, 




H NMR spectroscopic data (600 MHz, CDCl3) and 
13
C NMR 
spectroscopic data (125 MHz, CDCl3) are shown in Table 1 and Table 2. HREIMS 
m/z 334.1441 [M]
+
 (calcd. 334.1441 for C18H22O6). 
 
Compound 5 
Brown solid:     
    
-7.99 (MeOH, c1.00). UV λmax (MeOH) 210 (2.99), 251 (3.03) 





H NMR spectroscopic data (600 MHz, CDCl3) and 
13
C NMR 
spectroscopic data (125 MHz, CDCl3) are shown in Table 1 and Table 2. HRFABMS 
m/z 348.0780 [M+Na]
+
 (calcd. 348.0780 for C19H24O6Na). 
Compound 6 
Brown solid:     
    -10.1 (MeOH, c1.00). UV λmax (MeOH) 218 (3.06), 256 (3.00), 
291 (2.56) nm. IR υmax (KBr) 2937, 2835, 1705, 1666, 1600, 1515, 1271, 1225, 1176, 




H NMR spectroscopic data (600 MHz, CDCl3) and 
13
C 
NMR spectroscopic data (125 MHz, CDCl3) are shown in Table 1 and Table 2. 
HRFABMS m/z 379.1736 [M+H]
+
 (calcd. 379.1736 for C20H27O7). 
 
Compound 7 
Brown solid:     
    -101.4 (MeOH, c1.00). UV λmax (MeOH) 204 (4.79), 256 (4.54) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
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data (125 MHz, CD3OD) are shown in Table 3. HRFABMS m/z 463.1763 [M+Na]
+
 
(calcd. 463.1733 for C25H42O17Na ). 
 
Compound 8.  
Brown solid:  α  
     -0.02 (MeOH, c1.00); UV (MeOH) λmax (log ε) 289 (2.5945), 
261 (2.9541) , 215 (3.0790) nm; IR υmax (KBr) 3448, 2937, 1705, 1602, 1514, 1456, 




H NMR spectroscopic data (600 
MHz, CDCl3) and 
13
C NMR spectroscopic data (125 MHz, CDCl3), are shown in 
Table 4. HRFABMS m/z 391.1244 [M+Na]
+
 (calcd. 391.1244 for C18H24O8Na ). 
 
Compound 10 
Brown solid:     
    -77.8 (MeOH, c1.00). UV λmax (MeOH) 203 (4.87), 257 (4.55) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 5 and Table 6. HRFABMS m/z 639.2045 
[M+Na]
+
 (calcd. 639.2054 for C31H36O13Na ). 
 
Compound 11 
Brown solid: UV λmax (MeOH) 203 (4.92), 258 (4.53) nm. 
1
H NMR spectroscopic 
data (600 MHz, CD3OD) and 
13
C NMR spectroscopic data (125 MHz, CD3OD) are 
shown in Table 5 and Table 6.      
    -73.3 (c =0.10, MeOH). HRFABMS m/z 
669.2145 [M+Na]
+
 (calcd. 669.2159 for C32H38O14Na ). 
 
Compound 12 
Brown solid:     
    -121.5 (MeOH, c1.00). UV λmax (MeOH) 203 (4.91), 259 (4.52) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 5 and Table 6. HRFABMS m/z 669.2145 
[M+Na]
+
 (calcd. 669.2159 for C32H38O14Na ). 
 
Compound 13 
Brown solid:     





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 5 and Table 6.  HRFABMS m/z 
639.2045 [M+Na]
+
 (calcd. 639.2054 for C31H36O13Na ). 
 
Compound 14 
Brown solid:     
    -47.7 (MeOH, c1.00). UVλmax  (MeOH) 203 (5.00), 257 (4.54) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 7 and Table 8. HRFABMS m/z 739.2207 
[M+Na]
+
 (calcd. 739.739.2214 for C35H40O16Na ). 
 
Compound 15 
Brown solid:     
    -51.4 (MeOH, c1.00). UVλmax (MeOH) 204 (5.08), 259 (4.62) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 7 and Table 8. HRFABMS m/z 769.2330 
[M+Na]
+
 (calcd. 769.2320 for C36H42O17Na ). 
 
Compound 16 
Brown solid:     
    -49.8 (MeOH, c1.00). UV λmax (MeOH) 204 (5.08), 259 (4.62) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 7 and Table 8. HRFABMS m/z 769.2330 
[M+Na]
+





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR 
spectroscopic data (125 MHz, CD3OD) are shown in Table 7 and Table 8. HRFABMS 
m/z 825.2572 [M+Na]
+





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR 





 (calcd. 825.2582 for C39H46O18Na). 
 
Compound 19 
Brown solid:     
    -19.8 (MeOH, c1.00). UV λmax (MeOH) 204 (4.98), 257 (4.31) 
nm. 
1
H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR spectroscopic 
data (125 MHz, CD3OD) are shown in Table 9. HRFABMS m/z 677.2200 [M+Na]
+
 
(calcd. 677.2210 for C36H42O17Na ). 
 
Compound 20.  
Colorless oil:  α  
     0.71 (MeOH, c1.90); UV (MeOH) λmax (log ε) 284.5 (1.10), 





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR 
spectroscopic data (125 MHz, CD3OD) are shown in Table 10. HRFABMS m/z 
371.1129 [M-H]
-
 (calcd. for C20H19O7, 371.1131). 
 
Compound 21.  
Colorless oil:  α  
     1.57 (MeOH, c1.00); UV (MeOH) λmax (log ε) 283 (0.2183), 





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR 
spectroscopic data (125 MHz, CD3OD) are shown in Table 10. HRESIMS m/z 
371.1122 [M-H]
-
 (calcd. for C20H19O7, 371.1131). 
 
Compound 27.  
Yellow powder:  α  
     –0.51 (MeOH, c1.00); UV (MeOH) λmax (log ε) 286 (1.27), 





H NMR spectroscopic data (600 MHz, CD3OD) and 
13
C NMR 
spectroscopic data (125 MHz, CD3OD) are shown in Table 11. HRFABMS m/z 
261.0759 [M-H]
-





Compound 28.  
Yellow powder:  α  
     5.82 (MeOH, c1.00); UV (MeOH) λmax (log ε) 292 (2.23), 
281(2.38) , 271 (2.34), 226 (2.97), 212(2.95) nm; IR υmax (KBr) 3308, 2972, 





H NMR spectroscopic data (600 MHz, CDCl3) and 
13
C NMR 
spectroscopic data (125 MHz, CDCl3), are shown in Table 12. HRFABMS m/z 
300.1606 [M-H]
-
 (calcd. for C18H22NO3, 300.1600). 
 
Compound 31  
Yellow needles:  α  
     3.00 (MeOH, c1.00); UV (MeOH) λmax (log ε) 210 (2.93) , 





H NMR spectroscopic data (600 MHz, CDCl3) and 
13
C NMR 
spectroscopic data (125 MHz, CDCl3), are shown in Table 13. HREIMS m/z 288.0635 

























H NMR spectrum of 1 in CDCl3 
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HMQC spectrum of 1 in CDCl3 
 
 






















HMQC spectrum of 4 in CDCl3 
 
 







H COSY spectrum of 4 in CDCl3 
 



















HMQC spectrum of 5 in CDCl3 
 
 








H COSY spectrum of 5 in CDCl3 
 
 
NOE spectrum of 5 in CDCl3 (δH 3.26) 
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HMQC spectrum of 6 in CDCl3 
 
 








H COSY spectrum of 6 in CDCl3 
 
 



















HMQC spectrum of 7 in CD3OD 
 
 























HMQC spectrum of 8 in CDCl3 
 
 








H COSY spectrum of 8 in CDCl3 
 




NOE spectrum of 8 in CDCl3 (δH 2.38) 
 
NOE spectrum of 8 in CDCl3 (δH 2.80) 
 




NOE spectrum of 8 in CDCl3 (δH 5.08) 
 

















HMQC spectrum of 9 in CD3OD 
 
 
























HMQC spectrum of 10 in CD3OD 
 
 
























HMQC spectrum of 11 in CD3OD 
 
 

























HMQC spectrum of 12 in CD3OD 
 
 























HMQC spectrum of 13 in CD3OD 
 
 

























HMQC spectrum of 14 in CD3OD 
 
 

























HMQC spectrum of 15 in CD3OD 
 
 
























HMQC spectrum of 16 in CD3OD 
 
 























HMQC spectrum of 17 in CD3OD 
 
 
























HMQC spectrum of 18 in CD3OD 
 
 















HMQC spectrum of 19 in CD3OD 
 
 























HMQC spectrum of 20 in CD3OD 
 
 








H COSY spectrum of 20 in CD3OD 
 
 
NOE spectrum of 20 in CD3OD (δH 3.00) 
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 NOE spectrum of 20 in CD3OD (δH 3.77) 
NOE spectrum of 20 in CD3OD (δH 3.84) 
 




NOE spectrum of 20 in CD3OD (δH 4.45) 
 















HMQC spectrum of 21 in CD3OD 
 
 


























HMQC spectrum of 27 in CD3OD 
 
 























HMQC spectrum of 28 in CDCl3 
 
 





NOE spectrum of 28 in CDCl3 2.2 
 
NOE spectrum of 28 in CDCl3 2.46 
 
NOE spectrum of 28 in CDCl3 5.96 















HMQC spectrum of 28 in DMSO 
 
 





NOE spectrum of 28 in DMSO 2.85 
 
NOE spectrum of 28 in DMSO 4.77 
 







H NMR spectrum of 31 in CDCl3 
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HMQC spectrum of 31 in CDCl3 
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